

WestminsterResearch

<http://www.westminster.ac.uk/westminsterresearch>

**Extracellular vesicles and their nucleic acids for biomarker
discovery**

Momen Heravi, F., Getting, S.J. and Moschos, S.A.

NOTICE: this is the authors' version of a work that was accepted for publication in Pharmacology and Therapeutics. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Pharmacology and Therapeutics, doi: 10.1016/j.pharmthera.2018.08.002

The final definitive version in Pharmacology and Therapeutics is available online at:

<https://dx.doi.org/10.1016/j.pharmthera.2018.08.002>

© 2018. This manuscript version is made available under the CC-BY-NC-ND 4.0 license

<https://creativecommons.org/licenses/by-nc-nd/4.0/>

The WestminsterResearch online digital archive at the University of Westminster aims to make the research output of the University available to a wider audience. Copyright and Moral Rights remain with the authors and/or copyright owners.

Whilst further distribution of specific materials from within this archive is forbidden, you may freely distribute the URL of WestminsterResearch: (<http://westminsterresearch.wmin.ac.uk/>).

In case of abuse or copyright appearing without permission e-mail repository@westminster.ac.uk

Accepted Manuscript

Extracellular vesicles and their nucleic acids for biomarker discovery

Fatemeh Momen-Heravi, Stephen J. Getting, Sterghios Athanasios Moschos



PII: S0163-7258(18)30134-7
DOI: doi:[10.1016/j.pharmthera.2018.08.002](https://doi.org/10.1016/j.pharmthera.2018.08.002)
Reference: JPT 7257
To appear in: *Pharmacology and Therapeutics*

Please cite this article as: Fatemeh Momen-Heravi, Stephen J. Getting, Sterghios Athanasios Moschos , Extracellular vesicles and their nucleic acids for biomarker discovery. *Jpt* (2018), doi:[10.1016/j.pharmthera.2018.08.002](https://doi.org/10.1016/j.pharmthera.2018.08.002)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

P&T #23342

Extracellular vesicles and their nucleic acids for biomarker discovery

Fatemeh Momen-Heravi^{1,2}, Stephen J Getting^{2,3}, Sterghios Athanasios Moschos^{2,4}

¹ Division of Periodontics, Section of Oral and Diagnostic Sciences, Columbia University College of Dental Medicine, New York, New York, USA.

² Department of Biomedical Sciences, University of Westminster, London, UK.

³ Department of Life Sciences, University of Westminster, London, UK.

⁴ Department of Applied Sciences, Faculty of Health and Life Sciences, Northumbria University, Newcastle, UK.

Corresponding Author: Fatemeh Momen-Heravi, DDS, PhD, MPH, MS

Section of Oral, Diagnostic, and Rehabilitation Sciences Columbia University College of Dental Medicine, #PH7E, 630 W. 168 St., New York, NY 10032

Phone. 212.342.3008 Fax. 212.305.9313

ABSTRACT

Extracellular vesicles (EVs) are a heterogeneous population of vesicles originate from cells. EVs are found in different biofluids and carry different macromolecules, including proteins, lipids, and nucleic acids, providing a snapshot of the parental cells at the time of release. EVs have the ability to transfer molecular cargoes to other cells and can initiate different physiological and pathological processes. Mounting lines of evidence demonstrated that EVs' cargo and machinery is affected in disease states, positioning EVs as potential sources for the discovery of novel biomarkers.

In this review, we demonstrate a conceptual overview of the EV field with particular focus on their nucleic acid cargoes. Current knowledge of EV subtypes, nucleic acid cargo and pathophysiological roles are outlined, with emphasis placed on advantages against competing analytes. We review the utility of EVs and their nucleic acid cargoes as biomarkers and critically assess the newly available advances in the field of EV biomarkers and high throughput technologies. Challenges to achieving the diagnostic potential of EVs, including sample handling, EV isolation, methodological considerations, and bioassay reproducibility are discussed. Future implementation of 'omics-based technologies and integration of systems biology approaches for the development of EV-based biomarkers and personalized medicine are also considered.

Keywords: Biomarker, DNA, Extracellular vesicles, Exosomes, Nucleic acids, RNA

Abbreviations

Ago2 Argonaute-2

ALIX ALG-2-interacting protein X

CSF cerebrospinal fluid

ESCRT endosomal sorting complexes required for transport

EVs extracellular Vesicles

lnc-RNA long non-coding RNALPPs lipoprotein particles

miRNA microRNA

mtDNA mitochondrial DNA

MVBs multivesicular bodies

ncRNAs non-coding RNAs

NGS next generation sequencing

PAs protein aggregates

qRT-PCR quantitative reverse transcription PCR

RNA-Seq RNA sequencing

rRNA ribosomal RNA

SOP standard operating procedures

STARD standards for reporting diagnostic accuracy

tRNA transfer RNA

ACCEPTED MANUSCRIPT

Table of Contents

1. Introduction	5
1.1 Extracellular vesicles: subtypes and mechanisms of biogenesis.....	6
2. EVs as biomarkers: promises and pitfalls.....	8
2.1 Challenges for Standardization of EV biomarker discovery.....	11
2.2 EV isolation methods	12
2.2.1 Ultracentrifugation.....	13
2.2.2 Size exclusion techniques	14
2.2.3 Immune affinity isolation.....	15
2.2.4 Polymeric precipitation.....	15
2.2.5 Comparative methodology studies.....	16
2.3 Clinical, biological, and analytical challenges of EVs as biomarkers	18
3. Research ‘omics and the post-‘omic clinical era: the example of RNA and EVs.	20
3.1 EVs and transcriptomics.....	23
4. Mechanisms of RNA loading into the EVs	31
5. DNA content of EVs.....	34
6. Concluding remark and future challenges.....	38

1. Introduction

Extracellular vesicles (EVs) were historically considered to be membrane-derived cellular debris with no biological or clinical significance. However, evidence is amassing that EVs can exert multiple physiological and pathological functions as important mediators of intercellular communications (Fujita, Kosaka, Araya, Kuwano, & Ochiya, 2015; Momen-Heravi, Bala, Kodys, & Szabo, 2015; Szabo & Momen-Heravi, 2017; B. Xu, et al., 2017). Thus, such particles have been isolated from almost all cell types, mucosal and endogenous biofluids (blood, urine, saliva, cerebrospinal fluid, lymph, etc.) and have been implicated in key processes such as growth and development, cell-to-cell communication, immunomodulation, blood coagulation, and various stages of tumorigenesis (Al-Nedawi, et al., 2008; Buzas, Gyorgy, Nagy, Falus, & Gay, 2014; Del Conde, Shrimpton, Thiagarajan, & Lopez, 2005; Grange, et al., 2011; Gyorgy, et al., 2011). **Table 1** and **Table 2** exemplify EVs isolated from different cellular sources and biofluids.

Diverse molecular cargoes have been recovered from EVs, such as nucleic acids, proteins, and lipids. Notably, these cargoes appear to be protected against degrading enzymes such as nucleases and proteases: protection is afforded by a natural lipid bilayer capsule derived from the plasma membrane of the originating cell shedding the EV (Huang, et al., 2013; Lambertz, et al., 2015; Momen-Heravi, Bala, Bukong, & Szabo, 2014; Momen-Heravi, Bala, et al., 2015; Valadi, et al., 2007; Zappulli, Friis, Fitzpatrick, Maguire, & Breakefield, 2016). Importantly, the EV lipid bilayer and its enclosed cargo are stable under physicochemical conditions generally considered adverse for biological materials, such as long-term storage, multiple freeze-thaw cycles, and extreme pH (Nawaz, et al., 2014). Several groups have shown that pathological states such as oxidative stress, transformation, apoptosis, and ethanol-induced cell injury induce cells

to increase their EV release rate, simultaneously altering their composition to reflect the altered state of the cellular origin (Bergsmedh, et al., 2001; Eldh, et al., 2010; Jia, et al., 2014; Momen-Heravi, Bala, et al., 2015; Taylor & Gercel-Taylor, 2008; X. Zhang, et al., 2015). Together, these characteristics position EVs as a new, highly appealing class of biomarkers with strong diagnostic potential in the context of personalized medicine (Verma, Lam, Hebert, & Divi, 2015; Zocco, Ferruzzi, Cappello, Kuo, & Fais, 2014).

This review explores in depth the potential of EVs and EV-associated nucleic acids as biomarkers of clinical utility. Current knowledge of EV subtypes, nucleic acid cargo, nucleic acid sorting and pathophysiological role are outlined, with emphasis placed on advantages against competing analytes. Challenges to achieving the diagnostic potential of EVs including sample handling, EV isolation, methodological considerations, and bioassay reproducibility are discussed. These features will be presented in the context of systems biology and personalized medicine.

1.1 Extracellular vesicles: subtypes and mechanisms of biogenesis

The term 'EV' collectively refers to a heterogeneous vesicular population spanning 50 to 10,000 nm in size (**Figure1**). Distinct subpopulations include exosomes, microvesicles/microparticles, and apoptotic bodies (Momen-Heravi, et al., 2013; Raposo & Stoorvogel, 2013). These EVs are secreted from almost all cell types into the aqueous extracellular microenvironment and represent a snapshot of the cell status at the time of release, as defined by their components (Bukong, Momen-Heravi, Kodys, Bala, & Szabo, 2014; Momen-Heravi, Bala, et al., 2015). Beyond size, which is itself inadequate (Witwer, et al., 2013), biophysical characteristics such as density,

mode of biogenesis, and molecular markers such as CD63, CD81 and Annexin V are used to classify EVs as outlined in **Figure 1**.

Exosomes are the smallest (30-100 nm) and most heavily studied subpopulation of EVs (Braicu, et al., 2015; Thery, Ostrowski, & Segura, 2009). These particles are generated by the exocytosis of multivesicular bodies (MVBs) (Barry, Pratico, Savani, & FitzGerald, 1998; Denzer, et al., 2000) (**Figure 2**). Microvesicles (also called shedding vesicles, shedding microvesicles, or microparticles) are approximately 100-1000 nm in diameter and originate from the outward budding of the plasma membrane (Momen-Heravi, et al., 2013). Apoptotic vesicles are a subpopulation of EVs that range from 100-2000 nm in diameter and are generated by the blebbing of plasma membrane of cells undergoing apoptosis. Larger apoptotic vesicles (1000-5000 nm) are referred to as apoptotic bodies and contain fragmented nuclei as well as fragmented cytoplasmic organelles (Buzas, et al., 2014; Gyorgy, et al., 2011).

The classification of extracellular vesicles can be based on size, density, protein composition, and cell specific markers (van der Pol, Boing, Harrison, Sturk, & Nieuwland, 2012; van der Pol, et al., 2010). One of these parameters may not be adequate alone, however, as, for example, vesicles originating from different biogenesis pathways might have overlapping diameter ranges (Kowal, et al., 2016; Witwer, et al., 2013). Thus, the terminology referring to exosomes and extracellular vesicles has changed substantially over the past decade and the words “exosomes”, “microvesicles”, and “microparticles” have been used interchangeably in the past (Momen-Heravi, et al., 2013; van der Pol, et al., 2012). In future, gaining a better understanding of vesicle formation will lead to the characterization of extracellular vesicles based on mode of origin and guidelines are published and will be updated by the International Society for EVs (Lotvall, et al., 2014). Nevertheless, current understanding of EV biogenesis is incomplete and further

confounded by inconsistencies in EV isolation and characterization protocols. However, the identification of vesicles by specific molecular patterns is expected to progressively deepen characterization of these biological products under refined, universally agreed criteria that will lead to more advanced models of EV classification. The presently understood roles of EVs in the pathogenesis of disease are summarized in **Table 3**.

2. EVs as biomarkers: promises and pitfalls

The National Institutes of Health define the term biomarker as “*a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention*” (Biomarkers Definitions Working, 2001). In this context, the data deluge obtained through comprehensive profiling of the genome, transcriptome, proteome, and metabolome in health and disease has catalyzed a paradigm shift on how basic biomedical research is conducted. Crucially, these data have repeatedly hinted at the potential for early, accurate disease diagnosis with high sensitivity. Personalized disease progression monitoring might also be achievable through identification or measurement of one or more of these biomarker classes- so called ‘biomarker signatures’.

Liquid biopsy for EV sampling offers a number of advantages over other diagnostic methods: Firstly, overall EV levels are usually elevated in disease – a finding that has been proposed as a simple disease measurement tool in itself, but also engendered skepticism over disease-specific value. Thus, a ‘general stress signal’ view is adopted by many (Buzas, et al., 2014; Jia, et al., 2014; King, Michael, & Gleadle, 2012; Momen-Heravi, Saha, et al., 2015). However, repeated evidence has emerged of EV enrichment with specific molecular components (RNAs, proteins, and lipids) that reflect the status of the parental cell; in many, but not all cases, these biomarkers are enriched in the EVs in a disease-specific manner (Akers, et al., 2013; Boukouris &

Mathivanan, 2015; Momen-Heravi, Saha, et al., 2015; Turchinovich, Weiz, Langheinze, & Burwinkel, 2011). Thus, these findings have motivated research beyond disease correlation into establishment of causality: as such EVs might represent not only robust vehicles of disease-specific biomarkers, but also therapeutic targets in themselves.

Secondly, the lipid bilayer of EVs contributes further to diagnostic utility by protecting biomacromolecules and stabilizing them from RNases, proteinases, and other enzymatic activity present in the biofluids. For example, in bovine milk, naturally existing microRNA (miRNA) and mRNA which were associated with EVs were shown to be resistant to adverse acidic conditions (treated for 1 h in an acidic (pH 1) solution) and RNase treatment while synthetic spiked-in miRNAs were prone to degradation under similar conditions (Izumi, et al., 2012; Kosaka, Izumi, Sekine, & Ochiya, 2010). Several other reports showed that the total yield of EV RNA is not significantly changed after treatment with RNase, irrespective of EV origin: cell culture media, serum, or plasma (Bukong, et al., 2014; Huang, et al., 2013; Momen-Heravi, et al., 2014; Momen-Heravi, Bala, et al., 2015). Thus EVs are very stable allowing storage for an extended period of time, in contrast to many biomarker assays that require processing of fresh biofluids (Kalra, et al., 2013). Furthermore, in a multiplex study on ovarian cancer patients which identified eight miRNAs for discrimination of ovarian cancer from benign ovarian disease, miRNA levels were not altered by pre-analytical variables such as collection and storage time (Taylor & Gercel-Taylor, 2008). Thus, analysis of biomarkers within the EV fraction of biofluids promises a potential solution against poor analyte stability and deviation from sample handling standard operating procedures (SOP), factors well known to confound the outcomes of clinical trials (Momen-Heravi, Saha, et al., 2015; Witwer, 2015; Witwer, et al., 2013).

Thirdly, notwithstanding therapeutic relevance and sampling robustness, EV-based analysis offers a substantial statistical advantage in reducing biological matrix complexity and thereby overall assay noise. This significant improvement facilitates considerably more specific and sensitive detection of low abundance biomacromolecules (Boukouris & Mathivanan, 2015; Momen-Heravi, Saha, et al., 2015; Willis & Lord, 2015) or analytes with varying levels within sub-compartments of a complex biological matrix. A simple analogy can be drawn with the value of cell sorting in diagnostic hematology (Jaye, Bray, Gebel, Harris, & Waller, 2012), as well as *in vivo* pharmacology (Moschos, et al., 2011). This is commonly referred to as the “less is more” principle: a smaller, but more defined sample is highly enriched for specific biomarkers during the exosomal sorting and isolation process, that would otherwise constitute only a very small proportion (less than 0.01% v/v) of an unprocessed biofluid sample (Properzi, Logozzi, & Fais, 2013). Thus, several studies reported increased sensitivity for EV-based biomarkers compared to whole serum and urine biomarkers (Logozzi, et al., 2009; Madhavan, et al., 2015; Ogata-Kawata, et al., 2014). For instance, miRNAs found in EVs isolated from sera of patients with colorectal cancers showed higher sensitivity (90%) compared to serum biomarkers CEA and CA19-9 (30.7 and 16% respectively) (Ogata-Kawata, et al., 2014). Similarly, in several studies, higher levels of disease-specific biomarkers were found in the EV-enriched fraction of biofluids compared to the EV-depleted fraction (Bala, et al., 2012; Madhavan, et al., 2015). For example, a miRNA subset enriched in EVs isolated from the serum of prostate cancer patients was hardly detectable in healthy subjects. In stark contrast, the most abundant miRNAs in EV-depleted sera were recovered from both healthy and prostate cancer subjects (Madhavan, et al., 2015). In line with these findings, in alcoholic hepatitis, serum/plasma miRNA-122 and miRNA-155 levels were correlated with liver damage and were predominantly associated with the

exosome-rich fraction (around 5 times more) compared to the non-exosome fraction (Bala, et al., 2012). Consequently, the potential value of EVs has not escaped the attention of the personalized medicine community (An, et al., 2015; Fais, et al., 2016; Verma, et al., 2015). However, there remain significant challenges in the commercialization of such approaches beyond centralized, specialist laboratories and especially in diagnostic kit format. Thus, whilst the US FDA enables regulated (CLIA) laboratories to carry out so-called 'homebrew' tests, including on fractions of samples such as EVs, marketing of such diagnostic tests in kit format requires up to phase III clinical trials and regulatory approval in line with the standards for reporting diagnostic accuracy (STARD) (Bossuyt, et al., 2003). In Europe regulations are presently less stringent, through the self-certification CE marking scheme, but this is expected to align closer with FDA standards within the coming 5-10 years (Moschos, 2012). Recent changes to this framework come in the form of the FDA's *de novo* regulatory path for diagnostics development. This route has been opened to enable new analytical methodologies with no previous golden standard, such as whole genome sequencing, to reach the market. However, as evidenced through several instances of FDA intervention (e.g. Theranos Inc.), sample processing, wherein EV enrichment falls, is considered a separate step to analyte measurement technology in the diagnostic SOP continuum. Thus, commercialization of EV enrichment technologies is expected to follow the 510k FDA pathway, requiring high levels of clinical rigor and validation ahead of diagnostic use marketing. This will most probably be achieved with enrichment device/process alignment with one or more innovative biomarkers, whose commercial value pivots on the SOP, stability, statistical, and the 'less is more' principles cornerstone to the utility of EVs for biomarker recovery. Thus, the predicted EV biomarker workflow is depicted in **Figure 3**.

2.1 Challenges for Standardization of EV biomarker discovery

Despite the great interest in the role of EVs in different pathological conditions, there exist important limitations at the pre-analytical, isolation, characterization, biological, clinical and post analytical levels. Together, these contribute to confound concordance between different studies and raise questions with regards to ultimate clinical value. In line with the importance of standardization in other separation-based diagnostic technologies, establishing an efficient, rapid and reproducible isolation method is crucial to analytical reproducibility. In the last few years a variety of EV isolation technologies have been developed with each technique providing specific advantages and disadvantages to downstream analytics. Consequently, the lack of standardization hinders the translational process. Validation studies pivot on the systematic, orthogonal transfer of methods from research to development, in a manner that is end user-friendly and as simplified as possible. Indeed, many of the presently available methods are inherently prone to variance or poorly suited to standardization for the diagnostic laboratory setting.

2.2 EV isolation methods

Although EVs have been successfully isolated from a range of biofluids including cerebrospinal fluid (CSF) (W. W. Chen, et al., 2013), plasma (Caby, Lankar, Vincendeau-Scherrer, Raposo, & Bonnerot, 2005), urine (Raj, Fiume, Capasso, & Pocsfalvi, 2012), serum (Momen-Heravi, Bala, et al., 2015), saliva (Sivadasan, et al., 2015), amniotic fluid (Asea, et al., 2008), pancreatic duct fluid (Zheng, et al., 2018), and breast milk (Lasser, et al., 2011), the enrichment methods have included ultracentrifugation, antibody-coated magnetic beads, microfluidic devices, polymeric precipitation technologies, size exclusion, sieving, porous nano-structures, and other new technologies (**Table 4**). Yet the impact of sample processing on study outcome is nothing new (Momen-Heravi, et al., 2013), and extends the paradigms of confounding factors reported for

various proteomics and transcriptomic methods, even metagenomics and microbiomic studies (Salter, et al., 2014). To date, none of these reported methods have been shown to offer consistent superiority, whether by diagnostic purpose, type of biofluid, EV subclass or clinical setting. Indeed, either one or a combination of these methods might be used. Selection of a preferred method is greatly dependent on the goal to be achieved as well as preconceptions, assumptions and individual laboratory habits. In general, researchers aim for high EV purity and yield, either at the whole population of EVs or a subclass (exosomes, microvesicles, apoptotic bodies). The choice, however, is based on concurrent trends for the target disease, perhaps specific mechanistic interests in the underlying pathology, but principally on grounds of resource intensity (cost effectiveness against process complexity). However, preferential aim tradeoffs should be made depending on the circumstances, with hypothesis-driven mechanistic considerations at the center of process selection in order to maximize effectiveness.

2.2.1 Ultracentrifugation

Traditionally, the gold standard and most commonly used protocol for EV isolation/purification is differential centrifugation, which involves multiple centrifugation and ultracentrifugation steps. As protocols vary between users, this may lead to inconsistencies in the recovery of EVs. In general, the centrifugation protocol starts with a low speed centrifugation (300-500 g for 10-15 min) to pellet cells, followed by a medium speed (10,000 to 20,000 g for 20 min) to eliminate larger vesicles and a final 100,000 g ultracentrifugation step for >2 h to pellet EVs (Momen-Heravi, 2017). The protocol should be optimized based on important factors such as viscosity (Momen-Heravi, Balaj, Alian, Trachtenberg, et al., 2012) and rotor type (k factor)(Jeppesen, et al., 2014). Thus, in conditions that alter sedimentation rate, or diseases that increase the viscosity

of biofluids such as hyperviscosity IgM syndromes, cryoglobulinaemia, and macroglobulinaemia, the dilution of biofluids prior to ultracentrifugation should be considered (Kwaan, 2010; Witwer, et al., 2013). Similarly, the rotor k-factor is a commonly ignored parameter that, nonetheless, underpins the rotor efficiency in pelleting particles. Briefly, the value of the k-factor is determined by the maximum angular velocity (ω) of a centrifuge (in rad/s) and the minimum and maximum radius (r) of the rotor (Langer, et al., 2003; Momen-Heravi, et al., 2013). Consequently, the k-factor can influence the purity and yield of EVs in the ultracentrifugation steps and can be utilized to predict the time required for achieving the desired sedimentation profile.

Last but not least, the substantial risk of co-precipitation of viruses and protein aggregates (PAs) should be considered where such particles are within the EV size range assayed (Momen-Heravi, et al., 2013). Often this is ignored in some protocols, where the first and second centrifugation steps are replaced by faster, higher purity microfiltration techniques (They, Amigorena, Raposo, & Clayton, 2006). To compensate and minimise such carry-over issues an extra purification step can be added after the last centrifugation step, such as sucrose gradient or immunomagnetic isolation (Bukong, et al., 2014; Momen-Heravi, 2017; Momen-Heravi, et al., 2013).

2.2.2 Size exclusion techniques

Size exclusion techniques, including ultrafiltration and chromatography, are a rapid and inexpensive alternative solution (Boing, et al., 2014; Lobb, et al., 2015). Although these methods can accommodate a large volume of biofluids, they are unable to concentrate EVs, selectively isolate subpopulations and, in the case of ultrafiltration, may cause deformation of large vesicles

(Witwer, et al., 2013). However, nanomembrane ultrafiltration concentrators such as the Millipore Centricon™ and Amicon® Ultra-15 Centrifugal Filter Devices can be used to simultaneously concentrate and filter the samples (Momen-Heravi, et al., 2014).

2.2.3 Immune affinity isolation

Immune isolation can increase EV purity and enable selective capture of specific subpopulations based on one or more surface markers. In this approach, antibodies against defined surface protein markers are used conjugated/coated on beads. The captured EVs are then typically separated using magnetic-bead principles (Momen-Heravi, et al., 2013; Nakai, et al., 2016). The approach is versatile and compatible with downstream analysis including western blotting, flow cytometry, electron microscopy and transcriptomics (Bukong, et al., 2014). Beyond antibodies, other affinity-based methods include synthetic peptides such as vinceremin that exhibit specific affinity for canonical heat shock proteins (Ghosh, et al., 2014), Tim4-affinity method (Nakai, et al., 2016), as well as target-specific, synthetic, single-stranded oligonucleotides (aptamers) (Webber, et al., 2014).

2.2.4 Polymeric precipitation

Some newly introduced isolation techniques such as the ExoQuick™ (System Biosciences), Exosome Isolation Kit (Life Technologies) and ExoSpin Exosome Purification Kit (Cell Guidance Systems) can facilitate sedimentation of EVs from solution during low speed centrifugation (10,000–20,000 g) by promoting the precipitation of vesicles with polyethylene glycol or other polymers. Although these kits are faster and more efficient than ultracentrifugation, they also precipitate PAs and lipoproteins. Interestingly, it has been

demonstrated that a combination of polymeric precipitation methods, followed by immune affinity isolation against e.g. the exosomal marker CD63, can lead to a high yield of pure exosome subpopulations (Momen-Heravi, et al., 2014). Given the success of combinatorial solutions, and the drive for SOP simplification, several new material engineering-based technologies have recently been introduced. However, clinical and comparative studies on their reproducibility and clinical efficiencies are limited.

2.2.5 Comparative methodology studies

The methods outlined above present a variety of physicochemical and biochemical means through which EV characterization can be approached. These have the potential to impact significantly on the constituents of the resulting processed sample matrix, thereby complicating the elucidation of the functional role of EVs, biomarker discovery efforts and targeted analytical assay development. Despite worldwide interest in this research area, only a limited number of comparative studies have been published in the literature to date.

Thus, a recent study investigating comparatively the expression profile of 375 miRNAs in EVs isolated from the sera of healthy individuals, either by ultracentrifugation or by polymer precipitation methods, reported that differences in the observed miRNA profile of EVs can be affected by the isolation method (Rekker, et al., 2014). Elsewhere, 100 nm-liposomes fabricated with 1,2-dioleoyl-sn-glycero-3-phosphocholine and cholesterol were used as a model system to assess the effect of isolation protocols on EV recovery and size distribution (Lane, Korbie, Anderson, Vaidyanathan, & Trau, 2015). Among the four different purification protocols evaluated (ExoSpin, Invitrogen kits, PureExo, and ultracentrifugation) the first two achieved up to 2 orders of magnitude higher EV yields. However, the authors did not characterize the

recovered synthetic vesicles based on surface morphology or physicochemical methods such as dynamic light scattering and tunable resistive pulse sensing (Lane, et al., 2015). Van Deun *et al.*, evaluated the role of different isolation protocols in downstream ‘omics approaches for biomarker discovery. Density gradient centrifugation (Optiprep) yielded purer CD-63 positive EV fractions with less contaminating proteins such as Argonaute-2 (Ago2) complexes (Van Deun, et al., 2014). Amongst other functions, Ago2 is a member of the RNA-induced silencing complex and is considered an extracellular RNA-binding protein which is associated with the both EV and non-EV related fraction (Arroyo, et al., 2011; Goldie, et al., 2014). This preparation revealed a unique mRNA profile enriched for translation machinery and ribosomal proteins (Van Deun, et al., 2014). In a study conducted by Alvarez *et al.*, ultracentrifugation (traditional protocol, in combination with filtration or sucrose cushion) was compared to two other precipitation-based methods (ExoQuick-TC, System BioSciences) (Alvarez, Khosroheidari, Kanchi Ravi, & DiStefano, 2012). The authors modified the ExoQuick protocol and increased final centrifugation speed to 10,000 g, instead of the 1,500 g recommended by the manufacturer. Maximal EV, miRNA, and mRNA yield was obtained using the modified exosome precipitation protocol and RNA quality was suitable for downstream profiling. Similarly, Bukong *et al.*, compared ultracentrifugation to the ExoQuick precipitation kit ahead of immune affinity isolation against CD63 (Bukong, et al., 2014). Although ExoQuick outperformed ultracentrifugation in terms of EV recovery, both methods resulted in very high purity, verified by the abundance of EVs and lack of PAs in transmission electron microscopy images. Moreover, western blotting showed high yield of exosomal marker, CD63, after isolation with both methods. Such a combined precipitation and immune affinity protocol was found to be well-suited for use in the clinic in terms of simplicity, speed and sample throughput.

Notwithstanding the impact of EV isolation methodology, protein or RNA isolation methods may also impact upon the outcome of downstream analytics. Thus, EV RNA patterns were reported to vary in size and composition after isolation using different methods (Eldh, Lotvall, Malmhall, & Ekstrom, 2012). Mouse MC/9 cells were cultured and EVs were isolated by ultracentrifugation. RNA was isolated from EVs using seven commercially available RNA isolation kits. Generally, column-based methods were reported to outperform phenol-only or combined phenol and column approaches in terms of RNA yield and the highest yield was achieved by miRCURYTM RNA with the mean of 21.8 μg versus 6.1 μg for Trizol. These studies clearly demonstrate a growing, and largely unmet need for standardization and validation in EV sample preparation. Although precipitation methods are amenable to rapid, highly scalable, and effective EV isolation, clinical protocols require careful consideration of the research question. Furthermore, assay migration between methods should be supported by well-controlled studies leading to verification of successful implementation in the clinic prior to use. Researchers and clinicians should pay special consideration to the type of target biofluid as well as the type of biomarker, as different methodologies might be better suited for alternative matrices and analytes to those commonly used by a research group (Akers, et al., 2015; Momen-Heravi, Balaj, Alian, Tigges, et al., 2012). Readers are thus advised to implement appropriate comparative and confirmatory protocols as part of their pilot work in preparation of large scale studies.

2.3 Clinical, biological, and analytical challenges of EVs as biomarkers

The methodological variance in the EV biomarker research continuum is further augmented through additional clinical, biological, and analytical challenges as reviewed in **Table 5**. A major

challenge in EV-based diagnostics is the complexity of EV secretion mechanisms in different pathological conditions; this is intertwined with the activation of a complex network of diverse, cross-talking molecular pathways with adaptive feedback loops. The biomarker field has shown repeatedly that patient stratification and better disease discrimination can be achieved through the use of more than one single marker of disease. Indeed, there are examples, including in the field of EV research, where combined analysis of different classes of analytes can substantially improve sensitivity and specificity (Madhavan, et al., 2015). Thus, Madhavan *et al.* reported an increase of pancreatic cancer-initiating cell protein markers including CD44v6, Tspan8, EpCAM, MET and CD104 as well as increases in the levels of miRNA-1246, miRNA-4644, miRNA-3976, and miRNA-4306 in the serum-exosomes of pancreatic cancer patients compared to patients with chronic pancreatitis, benign pancreatic tumor and healthy controls (Madhavan, et al., 2015). Crucially, combined measurement of proteins and exosomal miRNA in discriminating pancreatic cancer from other type of pancreatic diseases and health increased sensitivity compared to protein analysis or miRNA analysis. These results make a strong case for signature biomarkers to transcend analyte classes.

In addition, difference in EV subtypes (Ji, et al., 2014), secretion mechanisms, and cargo changes in various stages of disease (Valencia, et al., 2014) must be taken into consideration. For example, Ji *et al.* (Ji, et al., 2014), showed that a colon cancer carcinoma cell line (LIM1863) released two distinct subtypes of exosomes, enriched in apical surface sorting proteins or basolateral surface sorting protein. Deep sequencing and proteomic analysis of the two subpopulations showed distinct miRNA and proteome profiles (Ji, et al., 2014; Tauro, et al., 2013). Thus, *in vivo* and patient observations need to be supported by parallel evaluations in cell lines, tissue culture and primary cell research, with particular attention to mechanistic detail in

recapitulating the organism milieu. These efforts will help elucidate the role of an EV release event in disease and inform the likelihood of recovery from a given biological matrix.

Integration of affected biomarkers in systems biology models can inform the affected disease pathways, leading to the identification of causal biomarkers instead of simply correlational outputs and, by extension, point the way to nodal points of pharmacological intervention in a quantitative fashion (Cucurull-Sanchez, Spink, & Moschos, 2012). Most importantly, the system approach takes into account the interrelating biological roles of pathway components, making it less sensitive to biological heterogeneity.

Eventually, the concepts of stratified medicine and systems biology are expected to drive personalized medicine into producing truly tailored treatments based on underlying disease mechanisms relevant to individual patients. However, to achieve this, a range of novel disease-specific biomarkers with relation to specific dysregulated pathways needs to be identified. In addition, a reference profile for cell-specific and tissue specific EVs molecular signatures is needed. Qualitative and quantitative modeling of EV molecular signatures can pave the way for EV-based monitoring and prospective diagnosis. The conceptual framework of integrating ‘omics data, systems biology approaches, and personalized medicine in EV biomarker studies are depicted in **Figure 4**.

3. Research ‘omics and the post-‘omic clinical era: the example of RNA and EVs.

Accurate measurement of biomarkers, be they EV preparations or otherwise, pivots on analytical platform limit of detection, dynamic range, and the capacity of current technologies to comprehensively identify, interpret and manage the resulting data. Moreover, there is a critical

need for transparency and reproducibility in the pipeline of biomarker discovery, including patient recruitment, data gathering, and processing – the so called open science model. The approach presents a unique proposition in fundamentally altering our approach to unlocking mechanisms of disease and disrupting patient care.

New advances in high-throughput technologies have ushered in the era of ‘omics science- the simultaneous agnostic survey of tens to millions of biomarkers including, transcriptomics, proteomics, lipidomics and metabolomics (de Graaf, 2013; Kulkarni, Kannan, & Atreya, 2010). Although ‘omic technologies have been utilized in EV studies, the amount of literature is limited. Yet disease development is a complex process; inherited susceptibility and different environmental exposures can modulate disease risk and progression in an individual over time. These introduce dynamic interactions in the evolution of individual molecular mechanisms of disease initiation and progression. For example, the cancer genesis process is presently understood to be characterized by stochastic accumulation of mutations and dynamic evolution of clones (Li, Blount, Vaughan, & Reid, 2011). Thus, whole genome instability measurements and genome-based cell population heterogeneity have been linked to stages of cancer development (Li, et al., 2011; Odoux, et al., 2008). Currently, most cancer biomarkers do not reflect the evolutionary dynamic of cancer progression but rather focus on specific deregulated pathways. Development of biomarkers for cancer risk management should consider these stochastic and dynamic properties over time during neoplastic evolution. This approach is fundamentally different from the three-stage disease category model of ‘normal’, ‘symptom-free disease’, and ‘symptomatic disease’ commonly used in biomarker screening. In fact, using stochastic modeling might provide a framework for guiding future biomarker research to enable more accurate patient stratification into various risk groups, each with a different cancer risk

distribution, thereby facilitating adaptive cancer risk strategies. This method can enable the optimization of available resources and intervention timing based on particular biomarker sensitivity and specificity in predicting disease progression and prognosis among various risk groups that dynamically evolve over time. Of course, the challenge that remains is arriving at study numbers adequately powered to achieve statistically interpretable outcomes – an endeavor of national or perhaps international scale

Yet such an approach is not without precedent, albeit with considerably reduced levels of complexity: staging of cancers on account of histology has increased the granularity of our understanding and altered our approach to treatment. Progressively, this is further enriched as more and more clinically validated interventions and their associated biomarker solutions come online. Expanding on this principle by integrating clinical findings with research ‘omics towards the construction of large scale Bayesian models (where the probability of given states is estimated based on a given set of starting points) promises a ‘live’ treatment and response scenario. Presently, this is done empirically. However, by continuously repositioning the collective understanding of such a diverse disease against the equally disparate patient background and treatment outcomes might indeed present a more realistic and accurate approach for contextual biomarker validation, understanding of disease mechanisms, (O'Connell, Rao, Chaudhuri, & Baltimore, 2010; Willis & Lord, 2015) and personalized intervention to the benefit of all stakeholders: patients, clinicians and researchers. To achieve this, it is necessary to work towards etymological and methodological concordance, or at the very least, provide adequate bridging principles that will enable the necessary level of participation, i.e. on a global, continuous scale. However, there are few incentives to academics, institutions and the industry to share.

3.1 EVs and transcriptomics

Transcriptomics is the study of the complete set of transcripts in a particular cell, tissue, sample or organism for a given physiological or pathological condition (Z. Wang, Gerstein, & Snyder, 2009). The transcriptome includes protein-coding messenger RNA (mRNA) and non-coding RNA (ncRNA: miRNA, long non-coding RNA (lnc-RNA), ribosomal RNA (rRNA), transfer RNA (tRNA), and other ncRNAs) (Lindberg & Lundeberg, 2010; Okazaki, et al., 2002; Qian, Ba, Zhuang, & Zhong, 2014). Various RNA populations including mRNA, lnc-RNA, circular RNAs, small nuclear RNAs, ribosomal RNAs, piwi-interacting RNAs and transferred RNAs have been identified in EVs using high-throughput technologies (Lasda & Parker, 2016; Ma, et al., 2017; Nolte-'t Hoen, et al., 2012).

Since the transcriptome is a dynamic entity underpinning homeostasis, frequently altered during disease and treatment, transcriptome analysis has attracted a lot of attention in the study of EV function. This is challenged by the low abundance of EVs in biofluids. However, at least three approaches allow medium/high throughput detection of transcriptomic biomarkers including amplification based methods, hybridization-based microarrays, and Next Generation Sequencing (NGS). Amplification-based assays enable measurement of panels of both miRNA and mRNA and expand upon the concept of quantitative reverse transcription PCR (qRT-PCR). Popular examples include the SABiosciences PCR array, TaqMan OpenArray, TaqMan Gene Expression Assays, TaqMan TLDA microfluidic cards by Applied Biosystems, miScript miRNA PCR Array by Qiagen and miRCURY LNA qPCR by Exiqon. All these platforms offer high sensitivity and can precisely detect changes in tens to hundreds of individual nucleic acid levels whose existence is known *a priori* and for whom assays can be designed (Tiberio, Callari, Angeloni, Daidone, & Appierto, 2015). Advantages include a multi-log (5-9) linear dynamic range, resistance to

purification protocol changes and organic contaminations. However, these technologies are mostly limited to medium throughput and annotated genes supporting hypothesis-derived discovery (Koshiol, Wang, Zhao, Marincola, & Landi, 2010). Correlation and reproducibility of each platform in the context of EV-based biomarkers remains to be determined. It is, unfortunately, generally assumed that differences would reflect the minutiae of assay engineering differences with respect to target annotation and mechanism of amplification.

Hybridization-based assays (microarrays) are powerful tools for high-throughput evaluation of thousands of transcripts (hundreds to tens of thousands) in one assay and have been used in EV-based studies. There are two types of microarrays: short-oligomer microarrays (e.g. Agilent, Affymetrix Genechips, Nanostring), and long probe microarrays which include cDNA microarrays that may probe sequences up to a few hundred bases in length (Koltai & Weingarten-Baror, 2008). Microarrays are also limited to known target sequences, feature considerably reduced cost per analyte, but suffer less specificity, reduced dynamic range, and poor reproducibility (Tiberio, et al., 2015). Indeed, poor specificity has been demonstrated to drive discrepancies in gene-expression profiles between different probes targeting the same region of a given transcript (Draghici, Khatri, Eklund, & Szallasi, 2006; Koltai & Weingarten-Baror, 2008), whereas operator and day-to-day variability are common problems in microarray data analysis (Draghici, et al., 2006). For this reason, many a microarray-based study's outcomes are validated by qRT-PCR methods with little, if any, effort to detail and compensation for methodological bias or compatibility, but rather on the assumption that statistical significance across two analytical approaches is a reliable signifier of consistency.

Next generation sequencing combines the advantages of amplification-based 'omics with the throughput of microarrays to yield global sequence data agnostically (Auer & Doerge, 2010;

Cloonan, et al., 2009) that can inform variability over single nucleotide polymorphisms (SNP) (F. Xu, et al., 2012), alternative RNA splicing (Bryant, Priest, & Mockler, 2012), copy number variations (CNV) (H. Wang, Nettleton, & Ying, 2014), and differential expression RNA sequencing (RNA-seq) (Auer & Doerge, 2010) in a digital fashion. At first glance this is superior to either qRT-PCR or microarray approaches. Thus, the sequences of all transcripts in a sample are reverse transcribed into cDNA, prepared into a sequencing library, read, bioinformatically mapped against a reference genome and individually quantified at a cost per analyte (base) orders of magnitude lower than microarrays. At ~US\$400 several tens of terabytes of sequence data can be generated with billions of data points per sample. The resulting analytical feat requires expert computational know how and infrastructure to undertake. However, the technology is sensitive to the relative abundance of individual transcripts within a sample, amplification method artifacts, chemistry-related bias and detection technique-mediated error – notwithstanding computational limitations (aligner bias, reference genome version bias). Thus, low frequency transcripts require ‘deeper’ (i.e. more) sequencing at a risk of artifact detection and mis-identification. Furthermore, as sequence ligation (adapters) is common in many sequencing library preparation methods, ligase sequence preference artifacts have been described to influence transcript frequency detection (Sorefan, et al., 2012). Moreover, nucleic acid contaminants arising from the biological origin of the processing enzymes can also contribute to confounding datasets (Schmieder & Edwards, 2011; Tringe & Rubin, 2005). Presently, each of the four most popular, commercially available RNA sequencing platforms has its own significant advantages and disadvantages. Briefly, Illumina NGS is an evolution of microarray technology and the most widely adopted platform, as it is less prone to error on account of homopolymer regions (e.g. adenosine multimers A_n , where $n > 6$). However, as with microarrays, it is based on

imaging and base-by-base template extension, which makes it slow, costly and high maintenance. Moreover, it is subject to frequent chemistry and instrumentation updates that affect data quality and compatibility that may internally compromise studies or cross-study data comparisons. On the other hand, it is the only approach that has been used to date to generate RNA-Seq data directly on histology sections by applying clonal template amplification on tissue sections (Holley, et al., 2012). The Ion Torrent technology is based on semiconductor microchip pH sensors of nucleoside addition. This detection methodology dramatically accelerates the data yield rates and enables robust hand-held NGS at the bedside (DNA Electronics Ltd.), but has a lower throughput than Illumina and is hampered by homopolymer errors and insertion/deletion artifacts. Both Illumina and Ion Torrent presently have <400 bp sequence limits and require sample fragmentation and clonal amplification; this causes problems in the analysis of repetitive regions and introduces further risk of error. Pacific Biosciences on the other hand uses optical, real time, single molecule sequencing which permits reads of up to hundreds of thousands of bases in length, but is a very slow, error prone, high cost and large footprint platform. Similarly, Oxford Nanopore also offers real time single molecule sequencing, this time on a sequencer the size of a USB stick that uses conductivity across a synthetic lipid bilayer to analyze transcript sequences as these transverse an engineered protein pore. It is considerably cheaper and faster than Pacific Biosciences, but it is a temperature- and kinetic energy-sensitive, considerably lower throughput instrument with a much higher error rate. In the next few years more robust, solid-state nanopore technologies based on graphene and other materials are expected to replace biological nanopores. Thus, where Illumina and Ion Torrent are good for counting non-repetitive sequences, Pacific Biosciences and Oxford Nanopore are better at developing complex repetitive sequence scaffolds and for RNA-Seq splice variant enumeration. Few studies aim to bring

together the advantages offered by each platform on answering clearly specific research questions. Rather the community is absorbed by the commercial marketing efforts and accessing answers with the least possible resistance, often with the least useful value. To the best of our knowledge these methodologies have not been evaluated yet in single EV sequencing and, by extension, to comparative sequencing of individual EVs. Notably, although for many years the cost of these technologies drove analysis to focus on single replicates, presently, independent biological and technical replicates are considered necessary (Auer & Doerge, 2010).

In their effort to understand the role of EV in disease, the reader is directed to the several databases that have been introduced to publicly source datasets of studies investigating mRNA, miRNA, but also proteins in biofluids including Exocarta (Barupal, et al., 2015), ExcellmiRDB (Barupal, et al., 2015) and miRandola (Sikkema-Raddatz, et al., 2013). However, most of the studies in these databases utilized targeted as opposed to genome- wide association studies (Matullo, Naccarati, & Pardini, 2015). Since the targeted-approach is based on an *a priori* knowledge of gene function in disease pathogenesis, it is highly hypothesis-dependent and may overlook other active network components, negative/positive feedback loop elements and indeed RNA editing/splicing changes (Kim, Lee, Kim, Lee, & Kim, 2012; Tabor, Risch, & Myers, 2002). Moreover, false positive/negative error rates, in many cases not taken account of, confound data replication in follow-up studies (Tabor, et al., 2002). The reader is therefore advised to approach the interpretation and extrapolation of these results with caution.

Various report identified presence of full length and sometimes fragments of mRNAs in EVs (Lai, et al., 2015; Valadi, et al., 2007; Yokoi, et al., 2017). Mechanistically, mRNA in EVs derived from MC/9 cells (mouse mast cell line), translated to a functional protein (Valadi, et al., 2007). In another study, introduction of Gaussia luciferase mRNA in glioblastoma cells and

addition of EVs isolated from those glioblastoma cells to human brain microvascular endothelial cells resulted in translation of mRNA in recipient cells (Skog, et al., 2008). Eirin *et al.* (Eirin, et al., 2014), performed transcriptome profiling on EVs derived from mesenchymal stem cells of adipose origin. These contained mRNAs for transcription factors (e.g. NRIP1, POU3F1) and genes involved in angiogenesis and adipogenesis, genes involved in TGF β signaling pathway, and selected miRNAs. Gene ontology analysis revealed that these miRNAs might target genes and transcription factors that contribute to several cellular pathways, including angiogenesis, apoptosis, cellular transport, and proteolysis. Interestingly, this enrichment was selective; cytoskeleton and mitochondrial gene families were excluded from these EVs (Eirin, et al., 2014).

Contemporary to the explosion of interest in EVs, miRNAs became established as nodal regulators of gene networks: data indicated specific miRNA could drive cell phenotype. Thus, initially many EV transcriptomic surveys focused on this class of RNA analytes (Huang, et al., 2013), and later on focused on other type of ncRNAs such as Y-RNA (Huang, et al., 2013). In line with conclusions drawn from target gene enrichment analysis and functional experiments, these miRNAs might play important functions in protein phosphorylation, RNA splicing, and the modulation of immune functions (Huang, et al., 2013; Momen-Heravi, Bala, et al., 2015; Momen-Heravi, Saha, et al., 2015). However, miRNAs are present in biofluids in three forms: cell-derived EVs, high-density lipoprotein particles (LPPs), and Ago2 protein complexes (Gibbins, Mostowy, et al., 2012; Maas, De Vrij, & Broekman, 2014). The sorting of miRNA to the EVs is indeed specific and selective (Momen-Heravi, Bala, et al., 2015) and may include, amongst others, the miRNA motif and sumoylation of heterogeneous nuclear ribonucleoproteins C pathway (Villarroya-Beltri, et al., 2013), the neural sphingomyelinase 2-associated pathway (Kosaka, et al., 2013), and the RNA induced silencing complex-related pathway (Frank,

Sonenberg, & Nagar, 2010). On the other hand, the mechanism of extra-vesicular miRNA release is poorly understood. Nevertheless, there is strong biomarker and clinical diagnostic potential in EV miRNAs (R. J. Bryant, et al., 2012; Chiam, et al., 2015; Huang, et al., 2015; Jansen, et al., 2014; Matsumoto, et al., 2013; Momen-Heravi, Saha, et al., 2015; Silva, et al., 2011; Sole, Cortes-Hernandez, Felip, Vidal, & Ordi-Ros, 2015; H. Wang, Hou, et al., 2014).

ACCEPTED MANUSCRIPT

Table 6 demonstrates a summary of the use of EV-associated miRNAs in clinical settings for biomarker discovery.

It has been suggested that miRNA expression changes in biofluids might occur earlier than conventional biomarkers, but this is often overlooked or not evaluated at all ahead of designing clinical validation studies. For example, in cardiovascular ischemic events, circulating miRNAs (miRNA-1, -133a, and -133b) achieved their peak around 3h before the commonly used troponin I peak (D'Alessandra, et al., 2010). Similarly, markers of inflammation and damage in cardiovascular disease, such as C-reactive protein and cytokines are observed in a later stage than miRNA deregulation (Pepys & Hirschfield, 2003). Moreover, in acetaminophen-induced liver injury, increases in circulating miRNA-122 correlated well with the degree of liver injury and were detectable ahead of an increase in serum aminotransferases (ALT and AST) (Bala, et al., 2012). A recent study involving global RNA NGS revealed that of 15 different classes of transcripts detected, 4 circulating EV-associated sequences within the miRNA class were differentially expressed in relapsing-remitting multiple sclerosis patients versus healthy controls: miRNA-122-5p, miRNA-196b-5p, miRNA-301a-3p, and miR-532-5p (Selmaj, et al., 2017). Expression of these EV-associated miRNAs was significantly decreased during relapse in patients.

Complexity also arises from the apparently non-specific elevation of certain circulating miRNAs such as miRNA-21 (Tanaka, et al., 2013; H. Wang, Hou, et al., 2014), which confound identification of disease-specific miRNA profiles. Integrating miRNA panel data in systems biology as opposed to focusing on single miRNAs can, however, help facilitate patient classification. Alternatively, measuring commonly dysregulated miRNAs might offer value not in disease screening but in disease monitoring or prognosis studies (Witwer, 2015). For instance,

the levels of three non-specific cancer-related miRNAs, miRNA-21, -221, and -141 in blood plasma of prostate cancer patients have been demonstrated to be useful for predicting metastasis within patient subgroups (Yaman Agaoglu, et al., 2011). Another challenge involves the data normalization approach used. Thus, in RNA studies, including miRNA, target levels are typically expressed relevant to at least one, but more commonly more than three different RNA targets not influenced by the disease/treatment, as determined through comprehensive profiling of normative samples for each biofluid. Indeed, many published studies provide selections of normalizing targets without adequate supporting evidence, perhaps beyond habitual use. These variables, in addition to sample processing, should be standardized ahead of attempting to establish clinical utility in independent cohorts (Moldovan, et al., 2014). Alternatively, a unified means of cross-study normalization, perhaps through automated selection of common normalization features (e.g. common normalizing gene subsets) could be adopted. Interestingly, since the number of EVs and their associated miRNAs is increased in various diseases, it has been proposed that using the same volume of starting biofluid might be a more suitable and adequate approach as compared to standardizing the amount of EV-associated miRNA extracts (Momen-Heravi, Saha, et al., 2015; Witwer, et al., 2013). This is not dissimilar to the single analyte approach common to viraemia analytics used in research. However, the approach is superseded by the use of endogenous normalization and/or spike in controls. Thus, in the absence of a globally harmonized biomarker reporting and data integration system, it is our view that more meticulous studies, with better thought out controls, based on much larger patient cohorts along with side-by-side comparisons with clinical parameters and conventional biomarkers are required for evaluating the utility of EV-associated miRNAs.

4. Mechanisms of RNA loading into the EVs

It has been evidenced that cellular RNAs are selectively loaded into the EVs (Janas, Janas, Sapon, & Janas, 2015; Momen-Heravi, Bala, et al., 2015; Saha, Momen-Heravi, Kodys, & Szabo, 2016). A number of mechanisms, including endosomal pathways, miRNA pathways, and lipid-mediated RNA loading into EVs have been suggested. Late endosomal pathways are ubiquitin-independent and lead to the formation of exosomes (de Gassart, Geminard, Hoekstra, & Vidal, 2004). During MVB formation, cytosolic RNAs are taken up into intraluminal vesicles undergoing inward budding from the limiting membrane. Cytosolic RNAs can be taken up into the intraluminal vesicles undergoing inward budding from the limiting membrane during the formation of MVB (Janas, et al., 2015). In the late endosomal pathway, ALG-2-interacting protein X (ALIX) binding to the exosomal cargo molecules can drive MVBs to go through exosomal sorting pathways instead of lysosomal recycling pathways (Hurley & Odorizzi, 2012). ALIX binds to Ago2 and miRNAs and play a key role in the miRNA enrichment during EV biogenesis (Gibbins, Leblanc, et al., 2012; Iavello, et al., 2016). Mechanistic studies showed that ALIX knockdown did not influence the number of EVs, but it significantly decreased the miRNA content of the EVs (Iavello, et al., 2016).

Cellular processes that lead to RNA loading into the EVs can be dependent on miRNA sequence and pathways (Santangelo, et al., 2016; Villarroya-Beltri, et al., 2013). Specific short motifs present in miRNAs determine the sorting of miRNAs into the EVs. Heterogenous nuclear ribonucleoproteinsA2B1, a ubiquitous protein that controls the loading of specific miRNAs in the EVs, is controlled by sumoylation of the protein (Santangelo, et al., 2016). Major vault protein mediates selective sorting of tumor suppressor miRNAs into the EVs (Teng, et al., 2017). RNA-binding protein Y-box protein 1 binds to and is required for the secretion of specific miRNAs in EVs (Shurtleff, Temoche-Diaz, Karfilis, Ri, & Schekman, 2016). In hepatocytes,

RNA binding protein SYNCRIP is a component of the EVs and plays a mechanistic role in the sorting of miRNAs into the EVs (Santangelo, et al., 2016). SYNCRIP directly binds to specific miRNA enriched in the EVs sharing a common extra-seed sequence (Santangelo, et al., 2016). RNA binding-protein YBX1, which is essential for the selective sorting of miRNAs into the EVs, plays a role in sorting of other type of ncRNAs such as tRNA, Vault RNAs, and Y RNAs (Shurtleff, et al., 2017). Interestingly, new evidence indicates a role for posttranscriptional modification in sorting of RNA specific into EVs (Shurtleff, et al., 2017).

In addition, mechanisms of RNA sorting into the EVs have been suggested as a disposal mechanism for excessive miRNAs which are in excess of their targets (Squadrito, et al., 2014). Secretory mechanisms of RNA sorting in mammalian cells are dependent on ceramide and raft-like regions (Kosaka, Iguchi, et al., 2010). Ceramide elicits EV release and some EV-associated miRNAs are released via ceramide-dependent secretory mechanisms which is independent of endosomal sorting complexes required for transport (ESCRT) machinery (Kosaka, Iguchi, et al., 2010). Janas et al, (2015) suggested that the raft-like regions of MVB can function as a target for miRNAs. Thus, binding of miRNAs to the raft-like region of MVB leads to loading of miRNAs into the EVs and protect the miRNA from degradation independent of Ago proteins (Janas, et al., 2015). This hypothesis is evidenced by the high abundance of miRNA passenger strand and stability of EV-associated miRNAs in the absence of Ago2 (Bang, et al., 2014; Koppers-Lalic, et al., 2014).

Differential affinity of different types of RNA to the raft-like regions has been documented (Janas, Janas, & Yarus, 2006; Villarroja-Beltri, et al., 2013). RNAs with specific secondary structure showed high affinity for rafted domains in sphingomyelin-cholesterol-

phosphatidylcholine vesicles that mimic raft components of EV membranes (Carayon, et al., 2011; Janas, et al., 2015; Janas, et al., 2006). Thus, EVs secreted by human cells contain mRNA fragments that are enriched in 3'-untranslated regions which contains elements conferring subcellular localization of mRNA and are rich in miRNA-binding sites (Batagov & Kurochkin, 2013). Ceramidase converts ceramide to the sphingosine. Since ceramide is produced in the raft-like region, the presence of sphingosine molecules in the limiting membrane likely increases the affinity of RNA to the membrane (Janas, et al., 2015). Specific EV-sorting RNA motifs have been suggested for both mRNA and miRNA (Batagov & Kurochkin, 2013; Villarroya-Beltri, et al., 2013). In addition to the membrane binding motif, hydrophobic modifications such as methylations can increase the affinity to the raft-like regions (Janas, et al., 2015). Thus, tRNAs can have several hydrophobic modifications that increase the affinity of tRNAs to raft-liked regions of the membrane and have been recovered from EVs (Janas, Janas, & Yarus, 2012; Vojtech, et al., 2014).

5. DNA content of EVs

Genomic DNA biomarkers report genome-level changes using a variety of methods, including genome sequencing, qPCR and digital PCR (Pang, et al., 2015) to accurately report SNPs, CNVs, genomic rearrangements and rare genetic sequences that functionally underpin the pathophysiology of disease (Deyati, Younesi, Hofmann-Apitius, & Novac, 2013). This approach is most frequently used in oncology. However, tumor analytics have long been known to suffer operator and sampling biases. Thus, tumor heterogeneity is not fully represented within a given biopsy, irrespective of the analytical platform used. Yet genetic changes in tumor tissues are also mirrored in biofluids and EVs (San Lucas, et al., 2015; Verma, et al., 2015). Importantly, these extracellular DNA sources may capture a snap shot of the disease state to be used for diagnosis,

disease monitoring, and therapeutic stratifications – particularly in ‘deep sampling’ (i.e. NGS) or highly sensitive (e.g qPCR) methods (Momen-Heravi, Saha, et al., 2015), without the need for invasive biopsy. Presently NGS is restricted to highly specialized, centralised clinical settings worldwide with significant research activity and are not suited to disease screening in health care settings. NGS targeted to specific sequences relying on *a priori* data/hypothesis is more cost-effective, allows for deeper sampling of commonly mutated genes, can simplify NGS analytics and therefore is the leading approach pursued for diagnostic NGS dissemination (Sikkema-Raddatz, et al., 2013). Crucially, targeted NGS has comparable sensitivity and specificity for detection of disease-specific mutations to Sanger sequencing, but benefits from significantly higher levels of data yield, can report unexpected mutations in key genes and inform digitally mutation abundance (Meldrum, Doyle, & Tothill, 2011; Sikkema-Raddatz, et al., 2013).

At first glance, the presence of DNA in EVs would indicate their apoptotic/necrotic nature (DNA fragments) as opposed to their enrichment in actively produced vesicles such as exosomes. As a result, the utility of EV-associated DNA has so far been less explored. Nonetheless, double strand DNA, mitochondrial DNA (mtDNA), single strand DNA, and oncogenic amplifications have reportedly been detected in EVs (Balaj, et al., 2011; Guescini, Genedani, Stocchi, & Agnati, 2010; Kulkarni, et al., 2010; Skog, et al., 2008; Thakur, et al., 2014; Yanez-Mo, et al., 2015). Double strand DNA was isolated from EVs originating from different human cancer cell lines, including chronic myeloid leukemia and colorectal carcinoma (Thakur, et al., 2014). The amount of DNA in the EVs was substantially increased when pre-senescent normal human diploid fibroblasts were treated with DNA-damaging agents (Takahashi, et al., 2017). Reducing EV secretion induced cytoplasmic accumulation of nuclear DNA and triggered a reactive oxygen species-dependent DNA damage response in both senescent and non-senescent cells, which

resulted in the activation of innate immunity (Takahashi, et al., 2017). These results indicate that EVs maintain cellular hemostasis by preventing the cytoplasmic accumulation of harmful nuclear DNA and the DNA damage response in normal human cells.

Genomic DNA reflecting the mutational status of parental tumor cells was found in EVs (Lazaro-Ibanez, et al., 2014; T. H. Lee, et al., 2014; Thakur, et al., 2014). Double-stranded DNA fragments in the EVs ranging from 6 to 17 kb in size was found in circulating EVs of healthy patients and patients with pancreatic cancer (Cai, et al., 2013). DNase treatment suggested that the long fragments of double-stranded DNA were predominantly found within the exosomes rather than outside (Cai, et al., 2013). A recent study reported that more than 93% of amplifiable cell-free DNA in plasma is located in the EV fraction (Fernando, Jiang, Krzyzanowski, & Ryan, 2017). DNA containing amplification of the oncogenic *c-myc* gene was isolated from circulating EVs in glioblastoma patients (Balaj, et al., 2011). In another study, >10kb fragments of double stranded genomic DNA were detected in EVs originating from pancreatic cancer cells and sera of patients with pancreatic ductal adenocarcinoma. Additionally, whole genome sequencing demonstrated that serum exosomes from patients with pancreatic cancer contain genomic DNA originating from all 23 human chromosomes (Kahlert, et al., 2014). These findings suggest that EV-associated DNA might at least hold value as translational biomarkers in identifying parental cell mutations. Elsewhere, mtDNA has been isolated from glioblastoma and astrocyte-derived EVs but their functionality remains unclear (Guescini, et al., 2010). Moreover, whole-exome sequencing and genome-wide copy number profiles of EVs isolated from plasma and pleural fluid showed robust representation of the tumor DNA within the shed EV compartment in patients with pancreaticobiliary cancers (San Lucas, et al., 2015). In a recent study, the full mitochondrial genome was identified in circulating EVs of patients with hormonal therapy

resistance breast cancer. Functionally, mtDNA from EVs acted as an oncogenic signal and promoted activation of cancer stem-like cells and lead to formation of resistance niches in Oxidative phosphorylation-dependent breast cancer (Sansone, et al., 2017).

Circulating EVs from patients with breast, colorectal, and pancreatic cancer were able to transform BRCA1-KO human fibroblasts (Hamam, et al., 2016). Cai et al demonstrated that EV-derived DNA containing the BCR/ABL hybrid gene (from K562 cell supernatant) were detected in normal recipient human neutrophils after coculture (Cai, et al., 2013). The horizontally transferred EV-associated DNA localized to the nucleus, recruits nuclear factor κ B (NF- κ B), and was transcribed (Cai, et al., 2013). Treatment of RAT-1 cells (immortalized rat fibroblasts) with EVs containing H-ras DNA sequence, showed transient H-ras DNA for up to 30d following exposure to EVs and increased proliferation (T. H. Lee, et al., 2014). These reports support the notion of functional horizontal transfer of DNA via EVs, however, the stable integration of EV-related DNA into the recipient genome has not been demonstrated (T. H. Lee, et al., 2016).

Analyses of EVs derived from cancer cell lines and non-cancer-associated fibroblast lines demonstrated more abundance of DNA in cancer cell-derived EVs (Kahlert, et al., 2014). The mechanisms of DNA packaging in the EVs are being actively investigated and are not fully understood, but it may involve cell apoptosis (Atkin-Smith, et al., 2015), the presence of plasma membrane associated DNA (Cheng, Torkamani, Peng, Jones, & Lerner, 2012), or the release of genomic DNA in the cytosol (Byrd, et al., 2016; Shen, et al., 2015). It is plausible that the mechanisms enabling packaging of DNA within EVs are cell type-specific and dynamically regulated.

Crucially, actionable DNA mutations such as NOTCH1 (cell survival and apoptosis) and BRCA2 (DNA repair) as well as fusion genes with well-described causal roles in oncogenesis

(e.g. APBA, STXBP1, KRAS, p53, ACOT1 and LMCD1) were found in circulating EVs (Kahlert, et al., 2014; San Lucas, et al., 2015). Interestingly, different subpopulations of EVs (i.e. exosomes, microvesicles) have also been reported to carry different amounts of gDNA (Lazaro-Ibanez, et al., 2014). For instance the relative ratio of PTEN, TP53 and MLH1 gDNA fragments was reported to vary by EV subpopulation as quantified by qPCR, using the GAPDH housekeeping gene as a reference (Lazaro-Ibanez, et al., 2014). It is unclear however if GAPDH is indeed an EV ‘housekeeper’, or a normalizer selected habitually from RNA studies. Nevertheless, collectively, these studies suggest that the DNA content in circulating EVs might not necessarily reflect parent cell viability, but perhaps active shedding of genomic fragments as they become compromised through genomic instability, and lend further support to their clinical evaluation as minimally invasive liquid biopsies. However, more high-throughput studies are needed to establish the functional significance of EV- associated genetic material in various diseases (Yanez-Mo, et al., 2015).

6. Concluding remark and future challenges

EVs continue to gain increasing attention as major players of cell communication with strong potential as causal, clinical biomarkers. Translational success will pivot on appropriate quality assurance and method validation across the continuum of discovery to clinical implementation. As stable reservoirs of different biomolecules, EVs suffer fewer challenges than other analyte matrices, and have the potential to serve as high value liquid biopsies in clinical diagnostics. Profiling of EVs can accommodate tumor heterogeneity and can be relatively to completely non-invasive, based on the biofluid selected. The substantial progress in the isolation, characterization, and elucidation of the biogenesis and functional roles of EVs in various physiological and pathological states is balanced by the major challenges and urgent need for

methodological harmonization and better study structure. To translate EV utility from discovery to the clinical setting these challenges must be met at the pre-analytical, analytical and post-analytical phases. In this context, the adoption of systems biology approaches is likely to help resolve the analytical challenge of 'omic datasets, enabling focus on causal biomarkers and the transition of EV-based diagnostics to the exciting opportunity of truly personalized medicine.

Conflict of interest: The authors declare that there are no conflicts of interest.

Table 1- Extracellular vesicles (EVs) and their cellular sources.

Cell type	Class	Tissue origin	Cargo of EVs	Biological function	Reference
B cells	Primary	Haematopoietic	B220 (CD45R), BCR complex, CD9 and CD81 tetraspanin MHC-I and MHC-II	Interaction with extracellular matrix	(Clayton, et al., 2004; Saunderson, et al., 2008)
Huh 7.5 cells	Immortalized	Hepatocarcinoma cell line	miRNA-122	Sensitize monocytes to LPS and ethanol effect and induce pro-inflammatory phenotypes in monocytes	(Momen-Heravi, Bala, et al., 2015)
THP1 cells	Immortalized	Human acute monocytic leukemia	miRNA-27a	miRNA-27a cargo in monocyte-derived EVs can polarize monocytes into M2 macrophages	(Saha, Momen-Heravi, Kodys, & Szabo, 2015)
Human T cell blasts	Primary	Haematopoietic	bioactive Fas ligand and APO2 ligand	Promoting activation induced cell death	(Martinez-Lorenzo, et al., 1999; Monleon, et al., 2001)
TS/A cell line	Immortalized	Mammary adenocarcinoma	PGE2, TGF- β	Suppress immune responses, modifying myeloid precursors toward a more tolerogenic phenotype	(Xiang, et al., 2009)
MML-1 cells	Immortalized	Melanoma	miRNA-214-3p, hsa-miRNA-199a-3p and hsa-miRNA-155-5p	Melanoma progression	(Lunavat, et al., 2015)
Renal cancer stem cells	Immortalized	Human Renal Cancer	proangiogenic mRNAs and microRNAs	Stimulate angiogenesis, formation of lung pre-metastatic niche	(Grange, et al., 2011)
Dendritic cells	Primary	Myeloid precursor cell	CD40, DC-SIGN (abundant only on small/medium EVs) and CD80 (present on all EVs)	induce CD4+ T-cell activation in vitro, differential pathway activations by subclass of EVs	(Tkach, et al., 2017)
Endothelial cells (HUVEC)	Primary	Endothelium of veins from the umbilical cord	(lnc-RNAs) HOTAIR and MALAT1	Induce a pro-vascularization phenotype	(Lamichhane, Leung, Douti, & Jay, 2017)

Table 2- Disease-related EVs isolated from different human biofluids.

Type of biofluids	Disease	Molecular Cargo	Changes in number of EVs in the disease state	Reference
Serum				
	Alcoholic hepatitis	miRNA-122	Increased	(Momen-Heravi, Bala, et al., 2015)
	Glioblastoma	EGFRIII fusion	Increased	(Skog, et al., 2008)
Plasma				
	Melanoma	High protein content including Met oncoprotein, CD44, Hsp70	No change	(Peinado, et al., 2012)
	Nasopharyngeal carcinoma	EBV BART viral miRNA	Unknown	(Gourzones, et al., 2010)
	Breast cancer	Phosphoproteins in plasma EVs	Increased	(I. H. Chen, et al., 2017)
	Hepatitis C	Hepatitis C virus, miRNA-122	Increased	(Bukong, et al., 2014)
	Pre-eclampsia	TIMP-1 in cholera toxin B chain-EVs and Plasminogen Activator Inhibitor Type I in annexin V -EVs (AV-PAI)	Increased	(Tan, et al., 2017)
Milk				
	<i>Staphylococcus aureus</i> infection	bta-miRNA-142-5p, miRNA-223	Unknown	(Sun, et al., 2015)
Cerebrospinal fluid (CSF)				
	Alzheimer's disease	miRNA-9, miRNA-125b, miRNA-146a, miRNA-155	Unknown	(Alexandrov, et al., 2012)
	Glioblastoma	CD144, CD4, CD45	Increased	(Liu, Sun, & Lan, 2014)
Saliva				
	Healthy donors	Different miRNAs	Not applicable	(Michael, et al., 2010)
Pleural effusion				
	Pancreaticobiliary cancers	Genomic DNA and transcriptome reflecting copy number profiles, point mutations, gene fusions and mutational signatures	Unknown	(San Lucas, et al., 2015)
Urine				
	Incipient Diabetic Nephropathy	miRNA-145, miRNA-155, miRNA-130a	No change	(Barutta, et al., 2013)
	Bladder cancer	Cancer-related proteins	Increased	(J. Lee, et al., 2018)
Amniotic fluid				
	Mid-trimester of healthy pregnant women	Tubulin, Hsp72/Hsc73	Not applicable	(Asea, et al., 2008)
Semen				
	Healthy subjects	CD9, CD63, Host restriction factor mRNA	Not applicable	(Madison, Roller, & Okeoma, 2014)

Table 3: Role of extracellular vesicles in the pathogenesis of different diseases.

Disease	Reference
Infectious disease	
Parasitic trematodes/nematodes: immunomodulation	(Marcilla, et al., 2012)
Spongiform encephalopathies: spread of transmissible prions via the blood	(Saa, et al., 2014)
HIV: miRNAs transport involved in HIV-associated neuronal dysfunction, trans-infection of CD4+ T-cells, transfer of HIV-1 Nef to infected cells	(Hu, et al., 2012),(Wiley & Gummuluru, 2006),(McNamara, et al., 2018)
HCV: shuttling virus between hepatocytes, transfer of viral replication components	(Bukong, et al., 2014), (Longatti, Boyd, & Chisari, 2015)
Epstein–Barr virus: viral biogenesis and egress, exosome-dependent immune suppression in EBV-associated lymphomas	(Meckes, et al., 2013), (Pegtel, et al., 2010)
Cancer	
Promote angiogenesis, thrombosis, tumor cell proliferation, increase endothelial permeability	(Kucharzewska, et al., 2013),(Millimaggi, et al., 2007) (Schillaci, et al., 2017)
Promote a pro-tumor environment to harbor metastatic niches and formation of pre-metastatic niche in different organs	(Rana, Malinowska, & Zoller, 2013), (Costa-Silva, et al., 2015)
Modulating bone marrow-derived cells to generate a pro-vascular phenotype	(Peinado, et al., 2012)
Induce immune suppression favoring tumor escape mechanisms	(Clayton, Mitchell, Court, Mason, & Tabi, 2007),(Andreola, et al., 2002)
Liver disease	
Cross-talk and horizontal transfer of miRNA between hepatocytes and monocytes and activation of macrophages via Hsp90	(Momen-Heravi, Bala, et al., 2015), (Saha, et al., 2015), (Saha, et al., 2017)
Mediate intercellular communication between hepatocellular carcinoma cells	(Kogure, Lin, Yan, Braconi, & Patel, 2011)
Neurodegenerative disease	
Parkinson disease: Transfer of α syn and inducing autophagy	(Danzer, et al., 2012)
Regenerative and protective functions	
Human mesenchymal stem cell-derived EVs protected against glycerol or cisplatin-induced kidney injury	(Bruno, et al., 2009; Gatti, et al., 2011)
Mediate mobilization of autocrine Wnt10b to promote axonal regeneration in the injured central nervous system	(Tassew, et al., 2017)

Table 4: Overview of extracellular vesicle isolation techniques

Isolation Method (basic principal)	Indication	Advantages	Disadvantages
Ultracentrifugation (sedimentation based on size and density)	Large volume of biofluids	Most widely used standardized method, Can be combined with size exclusion and sucrose gradient method (Momen-Heravi, 2017)	Low efficiency, Long protocol, Costly, Recovery dependent on rotor k factor and viscosity and sedimentation efficiency (Momen-Heravi, 2017), risk of contamination/co precipitation with viruses (Bukong, et al., 2014), PAs (Momen-Heravi, et al., 2013), and LPPs (Yuana, Levels, Grootemaat, Sturk, & Nieuwland, 2014)
Size exclusion Filtration	Large volume of biofluids, Can be combined with Nano-membrane ultrafiltration concentrators (Momen-Heravi, et al., 2014)	Feasible, Inexpensive, Non-selectivity ^φ	Co-isolation of contaminants that are in size o EVs, Does not concentrate the EVs, Forcing EVs through filters may cause deformation and breakup of large vesicles (Witwer, et al., 2013)
Immune affinity isolation (antibody against specific EVs surface proteins)	High purity isolation of EVs, Isolation of sub-set of EVs, Isolation of EVs from viruses and LPPs	High specificity and selectivity (Nakai, et al., 2016), Isolating special sub-set of EVs and negative selection (Bukong, et al., 2014; Momen-Heravi, et al., 2013), Easy to be coupled with beads and low speed centrifugation	Cross reactivity of antibody, Costly, Low yield (Thery, et al., 2006), Expensive equipment
Microfluidic techniques (trapping EVs in micro channels)	Low volume of input biofluids	Can be combined by immune affinity methods (Liga, Vliegenthart, Oosthuyzen, Dear, & Kersaudy-Kerhoas, 2015) (Wu, et al., 2017)	Early stage of development, Low throughput, Lack of evidence regarding efficiency and downstream clinical utility in comparative studies, channel blocking.
Polymeric precipitation methods (reduce EV solubility and drive precipitation by dissolving polymers)	Both low and high volume of input biofluids	Efficient isolation, High yield of EV recovery and EV-associated RNA (Momen-Heravi, et al., 2014), Efficiency in clinical studies, Can be combined by immune	Cannot appreciably purify EVs from a protein mixture and viruses unless coupled with immune affinity methods (Bukong, et al., 2014)

		affinity methods to increase purity (Bukong, et al., 2014; Momen-Heravi, et al., 2014)	
Size exclusion chromatography (separation based on molecular weight and size)	Both low and high volume of input biofluids	Can be combined with ultracentrifugation, High purity of EVs, Low level of contaminations with PAs (Gamez-Valero, et al., 2016; Nordin, et al., 2015)	Need for specific equipment, Cannot sort EVs based on specific molecular patterns
Sieving methods (deriving filtration by pressure or electrophoresis) (Davies, et al., 2012)	Very low amount of input material (3ul-4ul) and rapid isolation	Shorter separation time compared to size exclusion (Davies, et al., 2012)	Low exosome recovery, Not suitable for large volume of biofluid, Lack of comparative studies and validation on clinical samples (Liga, et al., 2015)
Porous structures (capturing EVs through porous microstructures based on ciliated micropillar structure) (Z. Wang, et al., 2013)	Selectively trap particles in the range of 40-100 nm based on the research question	Fast trapping	Not suitable for isolation of larger particles, Not validated with clinical samples, Not suitable for handling large volume of biofluids, No analysis of cargo or comparative study available (Liga, et al., 2015), Time consuming to characterize the EVs isolated based on this method ^ϕ (Liga, et al., 2015) ^ψ (Z. Wang, et al., 2013)

ϕ Non-selectivity can be advantage in case that the researchers/clinicians are interested in isolating whole population of EVs and can be a disadvantage when isolation of a subset of EVs is of interest; ^ψ to proceed with imaging and characterization, it is necessary to dissolve the silicon nanowire in PBS buffer overnight.

Table 5: Challenges for using EVs for biomarker discovery

Causal factors	Examples of the effect of the causal factor in EV-biomarker concordance	References
Clinical and biological		
Circadian EV marker expression	Circadian EV expression of renal thiazide NaCl cotransporter and prostasin in urinary exosomes	(Castagna, et al., 2015)
Change of EV cargo in different course of disease that necessitate very well characterized study cohort and multiple sampling	Changes in the miRNA-cargo content within EVs as a mechanism influencing bone metastatic colonization	(Valencia, et al., 2014)
Heterogeneity in tumor microenvironment and tumorigenesis mechanisms	40% of all breast cancers contain hypoxic microenvironments that produce EVs with specific signature (contains miRNA-210)	(King, et al., 2012), (Thomas, et al., 2013)
Choosing the most clinically relevant biomarker at study design step	mRNA transcript levels and corresponding protein showed marked differences in side by side measurements	(B. Zhang, et al., 2014)
Individual variability (age, gender, genetic factors, ethnicity)	Both qualitatively and quantitatively, the protein content of EVs showed gender specificity in renal tubule-specific responses in infected rats; EVs isolated from prostate cancer tumors showed ethnically and tumor-specific signatures	(da Silveira, Winger, Bouma, & Carnevale, 2015), (RamachandraRao, et al., 2015), (Gonzales, et al., 2009)
Physical activity	Physical exercise induces rapid release of exosome subpopulation of EVs into the circulation	(Fruhbeis, Helmig, Tug, Simon, & Kramer-Albers, 2015)
Variation in signature of different subpopulation of EVs	Deep sequencing data showed the LIM1863 cells release different subpopulation of EVs harboring specific miRNA signature	(Ji, et al., 2014)
Difference between animal models and human studies	Differential expression level of miRNA-122 in alcoholic hepatitis mouse model and human subjects with alcoholic hepatitis	(Momen-Heravi, Saha, et al., 2015)
Technological, analytical and sample handling factors		
Difference in detection frequency of different techniques	Differences in detection frequency of IDH1 mutation copy number in CSF of patients with Glioblastoma by BEAMing and Droplet Digital PCR Analysis	(W. W. Chen, et al., 2013)
Limitation in type of biomarkers	miRNA biomarkers and protein biomarkers showed reduced sensitivity compared to combination of miRNA/proteins for pancreatic cancer diagnostics	(Madhavan, et al., 2015)
Collection, storage, and preservation of EVs	Freezing at -20°C caused a major loss in urinary EVs in contrast to storing at -80°C which lead to complete recovery of EVs compared to fresh urine, vortexing after thawing increase exosome recovery	(Zhou, et al., 2006)
High throughput sensitivity, dynamic range, and cost effectiveness	RNA-seq provide broader dynamic range compared to microarray	(Zhao, Fung-Leung, Bittner, Ngo, & Liu, 2014)
Choice of anticoagulant for plasma samples	Heparin can cause false negative PCR reads	(Beutler, Gelbart, & Kuhl,

Challenges in accurate measurement of cargo	Agilent Bioanalyzer small RNA kit is less accurate in quantifying miRNA after isolation of EVs, since presence ribosomal RNAs are not consistent in EVs	1990) (Eldh, et al., 2012), (Moldovan, et al., 2014)
--	---	--

ACCEPTED MANUSCRIPT

Table 6: Examples of EV-associated miRNA dysregulation detected in human diseases

Differentially expressed miRNAs	Disease	Biofluid	Controls	Isolation methods	Spike-in/endogenous controls	Reference
miRNA-21	Increased in Hepatocellular Carcinoma	Serum	Healthy controls/Chronic hepatitis B	Total Exosome Isolation Reagent (Invitrogen)	U6 snRNA	(H. Wang, H et al., 2014)
miRNA-192, miRNA-30a, miRNA-122	Increased in alcoholic hepatitis	Plasma	Healthy controls	Filtration/ExoQuick (System Biosciences)	miRNA-15a, spiked in Cel-39	(Momen-He Saha, et al., 2015)
miRNA-19b	Increased in prostate cancer patients	Urine	Healthy controls	High-speed centrifugation/Filtration	miRNA-16	(Iraci, Leona Gessler, Veg Pluchino, 2015)
A multi-biomarker panel (RNU6-1/miRNA-16-5p, miRNA-25-3p/miRNA-320a, let-7e-5p/miRNA-15b-5p, miRNA-30a-5p/miRNA-324-5p, miRNA-17-5p/miRNA-194-5p)	Increased in locally advanced esophageal adeno-carcinoma	Serum	Healthy controls/Barrett's esophagus	ExoQuick	Global normalization	(Chiam, et al., 2015)
miRNA-126, miRNA-199a	Increased levels inversely predict cardiovascular events	Plasma	Patients with stable coronary artery disease.	Ultracentrifugation	Spiked-in Cel-miRNA-39	(Jansen, et al., 2014)
miRNA-375, miRNA-141p	Increased in prostate cancer	Urine	Healthy controls	ExoMir extraction	snoRNAs (RNU44 and RNU48), Cel-miRNA-39	(R. J. Bryant et al., 2012)
let-7a, miRNA-1229, miRNA-1246, miRNA-150, miR-21, miRNA-223, miRNA-23a	Increased in colon cancer	Serum	Healthy control	Ultracentrifugation	Global normalization, miRNA-451	(Ogata-Kaw et al., 2014)
let-7f, miRNA-20b, miRNA-30e-3p	Decreased in non-small cell lung cancer	Plasma	Healthy controls	Immuno magnetic beads	miRNA-142-3p and miRNA-30b	(Silva, et al., 2011)
miRNA-1290, miRNA-375	Higher levels associated with poor survival of prostate cancer	Plasma	castration-resistant prostate cancer patients	ExoQuick	miRNA-30a-5p, miRNA-30e-5p	(Huang, et al., 2015)

miRNA-1246	Higher levels associated with aggressive form of prostate cancer	Serum	Disease free controls/ benign prostatic hyperplasia	Total Exosome Isolation Reagent	Global normalization, Spike-in controls (cel-miRNA-248, cel-miRNA-254, osa-miRNA-414, osa-miRNA442)	(Bhagirath, et al., 2018)
miRNA-29c	Negatively associated with early renal fibrosis in lupus nephritis	Urine	Healthy controls/ non-lupus chronic kidney disease	Ultracentrifugation	GAPDH (mRNA), RNU6	(Sole, et al., 2015)

Figure 1- Classification of extracellular vesicles

Figure 1- Classification of extracellular vesicles

Historically, EV classification was based on cellular origin. However, EVs can be more accurately categorized on the basis of their biogenesis.

Oncosomes: tumor microvesicles that transmit signaling complex between cells.

Ectosomes: vesicles secreted by human polymorphonuclear leukocytes

Microparticles: vesicles originated from pellets

Dexosomes: vesicles released from dendritic cells

Texosomes: vesicles derived from tumor cells

EV classification based on mode of biogenesis

Exosomes	Microvesicles	Apoptotic bodies
<ul style="list-style-type: none"> •Origin: budding of inter luminal multivesicular bodies of endosomal pathways •Size: 30-100 nm •Surface markers: Tetraspanins (CD61, CD81, CD82, CD9), ESCRT components, TSG101, Flotillin 1 and Flotillin 2, HSPs, ALIX, MFGE8 	<ul style="list-style-type: none"> •Origin: Outward budding of plasma membrane •Size: 50-1000 nm •Surface markers: AnnexinV, Integrins, CD40 ligand 	<ul style="list-style-type: none"> •Origin: Outward budding of plasma membrane in apoptotic cells •Size: 50-5000 nm •Surface Markers: AnnexinV, particularly enriched in phosphatidylserin

*ESCRT: Endosomal sorting complex required for transport complex, MFGE8: milk fat globule-EGF factor 8 protein, TSG101: tumor susceptibility gene 101, HSPs: heat shock proteins




Figure 2- Exosome biogenesis and secretion- Exosomes are generated from multivesicular bodies (MVBs) of the endosomal system. Early endosomes form after endocytosis and from MVBs in which cargo is packed in the exosomes by inward budding of the membrane. ESCRT machinery, mono-ubiquitination, the lipid raft and segregation into microdomains by ceramide have been described as facilitators of exosome biogenesis. MVBs can merge with lysosomes resulting in degradation of the cargo or with the plasma membrane which results in exosome release. This process is regulated by Rab GTPases. Exosomes contain different cargoes including Rab proteins, ALIX, MHC molecules, clathrins and transferrin receptors.




Figure 3- The EV biomarker workflow. An illustration of a pipeline in taking an EV-associated biomarker from bench to bedside. The EV biomarker workflow should align with the established paradigm of diagnostics development and might benefit within the opportunities of companion diagnostics development in pursuit of commercialization, diverse uptake and success in transforming patient care.




Figure 4- Frame work of integrating 'omic data in systems biology approaches in EV biomarker studies.

References

- Akers, J. C., Ramakrishnan, V., Kim, R., Phillips, S., Kaimal, V., Mao, Y., Hua, W., Yang, I., Fu, C. C., Nolan, J., Nakano, I., Yang, Y., Beaulieu, M., Carter, B. S., & Chen, C. C. (2015). miRNA contents of cerebrospinal fluid extracellular vesicles in glioblastoma patients. *J Neurooncol*, *123*, 205-216.
- Akers, J. C., Ramakrishnan, V., Kim, R., Skog, J., Nakano, I., Pingle, S., Kalinina, J., Hua, W., Kesari, S., Mao, Y., Breakefield, X. O., Hochberg, F. H., Van Meir, E. G., Carter, B. S., & Chen, C. C. (2013). MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): a platform for glioblastoma biomarker development. *PLoS One*, *8*, e78115.
- Al-Nedawi, K., Meehan, B., Micallef, J., Lhotak, V., May, L., Guha, A., & Rak, J. (2008). Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. *Nat Cell Biol*, *10*, 619-624.
- Alexandrov, P. N., Dua, P., Hill, J. M., Bhattacharjee, S., Zhao, Y., & Lukiw, W. J. (2012). microRNA (miRNA) speciation in Alzheimer's disease (AD) cerebrospinal fluid (CSF) and extracellular fluid (ECF). *Int J Biochem Mol Biol*, *3*, 365-373.
- Alvarez, M. L., Khosroheidari, M., Kanchi Ravi, R., & DiStefano, J. K. (2012). Comparison of protein, microRNA, and mRNA yields using different methods of urinary exosome isolation for the discovery of kidney disease biomarkers. *Kidney Int*, *82*, 1024-1032.
- An, T., Qin, S., Xu, Y., Tang, Y., Huang, Y., Situ, B., Inal, J. M., & Zheng, L. (2015). Exosomes serve as tumour markers for personalized diagnostics owing to their important role in cancer metastasis. *J Extracell Vesicles*, *4*, 27522.
- Andreola, G., Rivoltini, L., Castelli, C., Huber, V., Perego, P., Deho, P., Squarcina, P., Accornero, P., Lozupone, F., Lugini, L., Stringaro, A., Molinari, A., Arancia, G., Gentile, M., Parmiani, G., & Fais, S. (2002). Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. *J Exp Med*, *195*, 1303-1316.
- Arroyo, J. D., Chevillet, J. R., Kroh, E. M., Ruf, I. K., Pritchard, C. C., Gibson, D. F., Mitchell, P. S., Bennett, C. F., Pogosova-Agadjanyan, E. L., Stirewalt, D. L., Tait, J. F., & Tewari, M. (2011). Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. *Proc Natl Acad Sci U S A*, *108*, 5003-5008.
- Asea, A., Jean-Pierre, C., Kaur, P., Rao, P., Linhares, I. M., Skupski, D., & Witkin, S. S. (2008). Heat shock protein-containing exosomes in mid-trimester amniotic fluids. *J Reprod Immunol*, *79*, 12-17.
- Atkin-Smith, G. K., Tixeira, R., Paone, S., Mathivanan, S., Collins, C., Liem, M., Goodall, K. J., Ravichandran, K. S., Hulett, M. D., & Poon, I. K. (2015). A novel mechanism of generating extracellular vesicles during apoptosis via a beads-on-a-string membrane structure. *Nat Commun*, *6*, 7439.
- Auer, P. L., & Doerge, R. W. (2010). Statistical design and analysis of RNA sequencing data. *Genetics*, *185*, 405-416.
- Bala, S., Petrasek, J., Mundkur, S., Catalano, D., Levin, I., Ward, J., Alao, H., Kodys, K., & Szabo, G. (2012). Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. *Hepatology*, *56*, 1946-1957.
- Balaj, L., Lessard, R., Dai, L., Cho, Y. J., Pomeroy, S. L., Breakefield, X. O., & Skog, J. (2011). Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. *Nat Commun*, *2*, 180.
- Bang, C., Batkai, S., Dangwal, S., Gupta, S. K., Foinquinos, A., Holzmann, A., Just, A., Remke, J., Zimmer, K., Zeug, A., Ponimaskin, E., Schmiedl, A., Yin, X., Mayr, M., Halder, R., Fischer, A., Engelhardt, S., Wei, Y., Schober, A., Fiedler, J., & Thum, T. (2014). Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. *J Clin Invest*, *124*, 2136-2146.

- Barry, O. P., Pratico, D., Savani, R. C., & FitzGerald, G. A. (1998). Modulation of monocyte-endothelial cell interactions by platelet microparticles. *J Clin Invest*, *102*, 136-144.
- Barupal, J. K., Saini, A. K., Chand, T., Meena, A., Beniwal, S., Suthar, J. R., Meena, N., Kachhwaha, S., & Kothari, S. L. (2015). ExcellmiRDB for translational genomics: a curated online resource for extracellular microRNAs. *OMICS*, *19*, 24-30.
- Barutta, F., Tricarico, M., Corbelli, A., Annaratone, L., Pinach, S., Grimaldi, S., Bruno, G., Cimino, D., Taverna, D., Deregibus, M. C., Rastaldi, M. P., Perin, P. C., & Gruden, G. (2013). Urinary exosomal microRNAs in incipient diabetic nephropathy. *PLoS One*, *8*, e73798.
- Batagov, A. O., & Kurochkin, I. V. (2013). Exosomes secreted by human cells transport largely mRNA fragments that are enriched in the 3'-untranslated regions. *Biol Direct*, *8*, 12.
- Bergsmeth, A., Szeles, A., Henriksson, M., Bratt, A., Folkman, M. J., Spetz, A. L., & Holmgren, L. (2001). Horizontal transfer of oncogenes by uptake of apoptotic bodies. *Proc Natl Acad Sci U S A*, *98*, 6407-6411.
- Beutler, E., Gelbart, T., & Kuhl, W. (1990). Interference of heparin with the polymerase chain reaction. *Biotechniques*, *9*, 166.
- Bhagirath, D., Yang, T. L., Bucay, N., Sekhon, K., Majid, S., Shahryari, V., Dahiya, R., Tanaka, Y., & Saini, S. (2018). MicroRNA-1246 is an exosomal biomarker for aggressive prostate cancer. *Cancer Res*.
- Biomarkers Definitions Working, G. (2001). Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. *Clin Pharmacol Ther*, *69*, 89-95.
- Boing, A. N., van der Pol, E., Grootemaat, A. E., Coumans, F. A., Sturk, A., & Nieuwland, R. (2014). Single-step isolation of extracellular vesicles by size-exclusion chromatography. *J Extracell Vesicles*, *3*.
- Bossuyt, P. M., Reitsma, J. B., Bruns, D. E., Gatsonis, C. A., Glasziou, P. P., Irwig, L. M., Moher, D., Rennie, D., de Vet, H. C., Lijmer, J. G., & Standards for Reporting of Diagnostic Accuracy, G. (2003). The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. The Standards for Reporting of Diagnostic Accuracy Group. *Croat Med J*, *44*, 639-650.
- Boukouris, S., & Mathivanan, S. (2015). Exosomes in bodily fluids are a highly stable resource of disease biomarkers. *Proteomics Clin Appl*, *9*, 358-367.
- Braicu, C., Tomuleasa, C., Monroig, P., Cucuianu, A., Berindan-Neagoe, I., & Calin, G. A. (2015). Exosomes as divine messengers: are they the Hermes of modern molecular oncology? *Cell Death Differ*, *22*, 34-45.
- Bruno, S., Grange, C., Deregibus, M. C., Calogero, R. A., Saviozzi, S., Collino, F., Morando, L., Busca, A., Falda, M., Bussolati, B., Tetta, C., & Camussi, G. (2009). Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. *J Am Soc Nephrol*, *20*, 1053-1067.
- Bryant, D. W., Jr., Priest, H. D., & Mockler, T. C. (2012). Detection and quantification of alternative splicing variants using RNA-seq. *Methods Mol Biol*, *883*, 97-110.
- Bryant, R. J., Pawlowski, T., Catto, J. W., Marsden, G., Vessella, R. L., Rhee, B., Kuslich, C., Visakorpi, T., & Hamdy, F. C. (2012). Changes in circulating microRNA levels associated with prostate cancer. *Br J Cancer*, *106*, 768-774.
- Bukong, T. N., Momen-Heravi, F., Kodys, K., Bala, S., & Szabo, G. (2014). Exosomes from hepatitis C infected patients transmit HCV infection and contain replication competent viral RNA in complex with Ago2-miR122-HSP90. *PLoS Pathog*, *10*, e1004424.
- Buzas, E. I., Gyorgy, B., Nagy, G., Falus, A., & Gay, S. (2014). Emerging role of extracellular vesicles in inflammatory diseases. *Nat Rev Rheumatol*, *10*, 356-364.
- Byrd, A. K., Zybailov, B. L., Maddukuri, L., Gao, J., Marecki, J. C., Jaiswal, M., Bell, M. R., Griffin, W. C., Reed, M. R., Chib, S., Mackintosh, S. G., MacNicol, A. M., Baldini, G., Eoff, R. L., & Raney, K. D. (2016). Evidence That G-quadruplex DNA Accumulates in the Cytoplasm and Participates in Stress Granule Assembly in Response to Oxidative Stress. *J Biol Chem*, *291*, 18041-18057.

- Caby, M. P., Lankar, D., Vincendeau-Scherrer, C., Raposo, G., & Bonnerot, C. (2005). Exosomal-like vesicles are present in human blood plasma. *Int Immunol*, *17*, 879-887.
- Cai, J., Han, Y., Ren, H., Chen, C., He, D., Zhou, L., Eisner, G. M., Asico, L. D., Jose, P. A., & Zeng, C. (2013). Extracellular vesicle-mediated transfer of donor genomic DNA to recipient cells is a novel mechanism for genetic influence between cells. *J Mol Cell Biol*, *5*, 227-238.
- Carayon, K., Chaoui, K., Ronzier, E., Lazar, I., Bertrand-Michel, J., Roques, V., Balor, S., Terce, F., Lopez, A., Salome, L., & Joly, E. (2011). Proteolipidic composition of exosomes changes during reticulocyte maturation. *J Biol Chem*, *286*, 34426-34439.
- Castagna, A., Pizzolo, F., Chiecchi, L., Morandini, F., Channavajjhala, S. K., Guarini, P., Salvagno, G., & Olivieri, O. (2015). Circadian exosomal expression of renal thiazide-sensitive NaCl cotransporter (NCC) and prostaticin in healthy individuals. *Proteomics Clin Appl*, *9*, 623-629.
- Chen, I. H., Xue, L., Hsu, C. C., Paez, J. S., Pan, L., Andaluz, H., Wendt, M. K., Iliuk, A. B., Zhu, J. K., & Tao, W. A. (2017). Phosphoproteins in extracellular vesicles as candidate markers for breast cancer. *Proc Natl Acad Sci U S A*, *114*, 3175-3180.
- Chen, W. W., Balaj, L., Liao, L. M., Samuels, M. L., Kotsopoulos, S. K., Maguire, C. A., Loguidice, L., Soto, H., Garrett, M., Zhu, L. D., Sivaraman, S., Chen, C., Wong, E. T., Carter, B. S., Hochberg, F. H., Breakefield, X. O., & Skog, J. (2013). BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles. *Mol Ther Nucleic Acids*, *2*, e109.
- Cheng, J., Torkamani, A., Peng, Y., Jones, T. M., & Lerner, R. A. (2012). Plasma membrane associated transcription of cytoplasmic DNA. *Proc Natl Acad Sci U S A*, *109*, 10827-10831.
- Chiam, K., Wang, T., Watson, D. I., Mayne, G. C., Irvine, T. S., Bright, T., Smith, L., White, I. A., Bowen, J. M., Keefe, D., Thompson, S. K., Jones, M. E., & Hussey, D. J. (2015). Circulating Serum Exosomal miRNAs As Potential Biomarkers for Esophageal Adenocarcinoma. *J Gastrointest Surg*, *19*, 1208-1215.
- Clayton, A., Mitchell, J. P., Court, J., Mason, M. D., & Tabi, Z. (2007). Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2. *Cancer Res*, *67*, 7458-7466.
- Clayton, A., Turkes, A., Dewitt, S., Steadman, R., Mason, M. D., & Hallett, M. B. (2004). Adhesion and signaling by B cell-derived exosomes: the role of integrins. *FASEB J*, *18*, 977-979.
- Cloonan, N., Xu, Q., Faulkner, G. J., Taylor, D. F., Tang, D. T., Kolle, G., & Grimmond, S. M. (2009). RNA-MATE: a recursive mapping strategy for high-throughput RNA-sequencing data. *Bioinformatics*, *25*, 2615-2616.
- Costa-Silva, B., Aiello, N. M., Ocean, A. J., Singh, S., Zhang, H., Thakur, B. K., Becker, A., Hoshino, A., Mark, M. T., Molina, H., Xiang, J., Zhang, T., Theilen, T. M., Garcia-Santos, G., Williams, C., Ararso, Y., Huang, Y., Rodrigues, G., Shen, T. L., Labori, K. J., Lothe, I. M., Kure, E. H., Hernandez, J., Doussot, A., Ebbesen, S. H., Grandgenett, P. M., Hollingsworth, M. A., Jain, M., Mallya, K., Batra, S. K., Jarnagin, W. R., Schwartz, R. E., Matei, I., Peinado, H., Stanger, B. Z., Bromberg, J., & Lyden, D. (2015). Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. *Nat Cell Biol*, *17*, 816-826.
- Cucurull-Sanchez, L., Spink, K. G., & Moschos, S. A. (2012). Relevance of systems pharmacology in drug discovery. *Drug Discov Today*, *17*, 665-670.
- D'Alessandra, Y., Devanna, P., Limana, F., Straino, S., Di Carlo, A., Brambilla, P. G., Rubino, M., Carena, M. C., Spazzafumo, L., De Simone, M., Micheli, B., Biglioli, P., Achilli, F., Martelli, F., Maggiolini, S., Marenzi, G., Pompilio, G., & Capogrossi, M. C. (2010). Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. *Eur Heart J*, *31*, 2765-2773.
- da Silveira, J. C., Winger, Q. A., Bouma, G. J., & Carnevale, E. M. (2015). Effects of age on follicular fluid exosomal microRNAs and granulosa cell transforming growth factor- β signalling during follicle development in the mare. *Reprod Fertil Dev*.

- Danzer, K. M., Kranich, L. R., Ruf, W. P., Cagsal-Getkin, O., Winslow, A. R., Zhu, L., Vanderburg, C. R., & McLean, P. J. (2012). Exosomal cell-to-cell transmission of alpha synuclein oligomers. *Mol Neurodegener*, 7, 42.
- Davies, R. T., Kim, J., Jang, S. C., Choi, E. J., Gho, Y. S., & Park, J. (2012). Microfluidic filtration system to isolate extracellular vesicles from blood. *Lab Chip*, 12, 5202-5210.
- de Gassart, A., Geminard, C., Hoekstra, D., & Vidal, M. (2004). Exosome secretion: the art of reutilizing nonrecycled proteins? *Traffic*, 5, 896-903.
- de Graaf, D. (2013). Multi-omic biomarkers unlock the potential of diagnostic testing. *MLO Med Lab Obs*, 45, 40, 42.
- Del Conde, I., Shrimpton, C. N., Thiagarajan, P., & Lopez, J. A. (2005). Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. *Blood*, 106, 1604-1611.
- Denzer, K., van Eijk, M., Kleijmeer, M. J., Jakobson, E., de Groot, C., & Geuze, H. J. (2000). Follicular dendritic cells carry MHC class II-expressing microvesicles at their surface. *J Immunol*, 165, 1259-1265.
- Deyati, A., Younesi, E., Hofmann-Apitius, M., & Novac, N. (2013). Challenges and opportunities for oncology biomarker discovery. *Drug Discov Today*, 18, 614-624.
- Draghici, S., Khatiri, P., Eklund, A. C., & Szallasi, Z. (2006). Reliability and reproducibility issues in DNA microarray measurements. *Trends Genet*, 22, 101-109.
- Eirin, A., Riestler, S. M., Zhu, X. Y., Tang, H., Evans, J. M., O'Brien, D., van Wijnen, A. J., & Lerman, L. O. (2014). MicroRNA and mRNA cargo of extracellular vesicles from porcine adipose tissue-derived mesenchymal stem cells. *Gene*, 551, 55-64.
- Eldh, M., Ekstrom, K., Valadi, H., Sjostrand, M., Olsson, B., Jernas, M., & Lotvall, J. (2010). Exosomes communicate protective messages during oxidative stress; possible role of exosomal shuttle RNA. *PLoS One*, 5, e15353.
- Eldh, M., Lotvall, J., Malmhall, C., & Ekstrom, K. (2012). Importance of RNA isolation methods for analysis of exosomal RNA: evaluation of different methods. *Mol Immunol*, 50, 278-286.
- Fais, S., O'Driscoll, L., Borrás, F. E., Buzas, E., Camussi, G., Cappello, F., Carvalho, J., Cordeiro da Silva, A., Del Portillo, H., El Andaloussi, S., Ficko Trcek, T., Furlan, R., Hendrix, A., Gursel, I., Kralj-Iglic, V., Kaeffer, B., Kosanovic, M., Lekka, M. E., Lipps, G., Logozzi, M., Marcilla, A., Sammar, M., Llorente, A., Nazarenko, I., Oliveira, C., Pocsfalvi, G., Rajendran, L., Raposo, G., Rohde, E., Siljander, P., van Niel, G., Vasconcelos, M. H., Yanez-Mo, M., Yliperttula, M. L., Zarovni, N., Zavec, A. B., & Giebel, B. (2016). Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine. *ACS Nano*, 10, 3886-3899.
- Fernando, M. R., Jiang, C., Krzyzanowski, G. D., & Ryan, W. L. (2017). New evidence that a large proportion of human blood plasma cell-free DNA is localized in exosomes. *PLoS One*, 12, e0183915.
- Frank, F., Sonenberg, N., & Nagar, B. (2010). Structural basis for 5'-nucleotide base-specific recognition of guide RNA by human AGO2. *Nature*, 465, 818-822.
- Fruhbeis, C., Helmig, S., Tug, S., Simon, P., & Kramer-Albers, E. M. (2015). Physical exercise induces rapid release of small extracellular vesicles into the circulation. *J Extracell Vesicles*, 4, 28239.
- Fujita, Y., Kosaka, N., Araya, J., Kuwano, K., & Ochiya, T. (2015). Extracellular vesicles in lung microenvironment and pathogenesis. *Trends Mol Med*, 21, 533-542.
- Gamez-Valero, A., Monguio-Tortajada, M., Carreras-Planella, L., Franquesa, M., Beyer, K., & Borrás, F. E. (2016). Size-Exclusion Chromatography-based isolation minimally alters Extracellular Vesicles' characteristics compared to precipitating agents. *Sci Rep*, 6, 33641.

- Gatti, S., Bruno, S., Deregibus, M. C., Sordi, A., Cantaluppi, V., Tetta, C., & Camussi, G. (2011). Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury. *Nephrol Dial Transplant*, *26*, 1474-1483.
- Ghosh, A., Davey, M., Chute, I. C., Griffiths, S. G., Lewis, S., Chacko, S., Barnett, D., Crapoulet, N., Fournier, S., Joy, A., Caissie, M. C., Ferguson, A. D., Daigle, M., Meli, M. V., Lewis, S. M., & Ouellette, R. J. (2014). Rapid isolation of extracellular vesicles from cell culture and biological fluids using a synthetic peptide with specific affinity for heat shock proteins. *PLoS One*, *9*, e110443.
- Gibbings, D., Leblanc, P., Jay, F., Pontier, D., Michel, F., Schwab, Y., Alais, S., Lagrange, T., & Voinnet, O. (2012). Human prion protein binds Argonaute and promotes accumulation of microRNA effector complexes. *Nat Struct Mol Biol*, *19*, 517-524, S511.
- Gibbings, D., Mostowy, S., Jay, F., Schwab, Y., Cossart, P., & Voinnet, O. (2012). Selective autophagy degrades DICER and AGO2 and regulates miRNA activity. *Nat Cell Biol*, *14*, 1314-1321.
- Goldie, B. J., Dun, M. D., Lin, M., Smith, N. D., Verrills, N. M., Dayas, C. V., & Cairns, M. J. (2014). Activity-associated miRNA are packaged in Map1b-enriched exosomes released from depolarized neurons. *Nucleic Acids Res*, *42*, 9195-9208.
- Gonzales, P. A., Pisitkun, T., Hoffert, J. D., Tchapyjnikov, D., Star, R. A., Kleta, R., Wang, N. S., & Knepper, M. A. (2009). Large-scale proteomics and phosphoproteomics of urinary exosomes. *J Am Soc Nephrol*, *20*, 363-379.
- Gourzones, C., Gelin, A., Bombik, I., Klibi, J., Verillaud, B., Guigay, J., Lang, P., Temam, S., Schneider, V., Amiel, C., Baconnais, S., Jimenez, A. S., & Busson, P. (2010). Extra-cellular release and blood diffusion of BART viral micro-RNAs produced by EBV-infected nasopharyngeal carcinoma cells. *Virology*, *7*, 271.
- Grange, C., Tapparo, M., Collino, F., Vitillo, L., Damasco, C., Deregibus, M. C., Tetta, C., Bussolati, B., & Camussi, G. (2011). Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. *Cancer Res*, *71*, 5346-5356.
- Guescini, M., Genedani, S., Stocchi, V., & Agnati, L. F. (2010). Astrocytes and Glioblastoma cells release exosomes carrying mtDNA. *J Neural Transm*, *117*, 1-4.
- Gyorgy, B., Szabo, T. G., Pasztoi, M., Pal, Z., Misjak, P., Aradi, B., Laszlo, V., Pallinger, E., Pap, E., Kittel, A., Nagy, G., Falus, A., & Buzas, E. I. (2011). Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. *Cell Mol Life Sci*, *68*, 2667-2688.
- Hamam, D., Abdouh, M., Gao, Z. H., Arena, V., Arena, M., & Arena, G. O. (2016). Transfer of malignant trait to BRCA1 deficient human fibroblasts following exposure to serum of cancer patients. *J Exp Clin Cancer Res*, *35*, 80.
- Holley, T., Lenkiewicz, E., Evers, L., Tembe, W., Ruiz, C., Gsponer, J. R., Rentsch, C. A., Bubendorf, L., Stapleton, M., Amorese, D., Legendre, C., Cunliffe, H. E., McCullough, A. E., Pockaj, B., Craig, D., Carpten, J., Von Hoff, D., Iacobuzio-Donahue, C., & Barrett, M. T. (2012). Deep clonal profiling of formalin fixed paraffin embedded clinical samples. *PLoS One*, *7*, e50586.
- Hu, G., Yao, H., Chaudhuri, A. D., Duan, M., Yelamanchili, S. V., Wen, H., Cheney, P. D., Fox, H. S., & Buch, S. (2012). Exosome-mediated shuttling of microRNA-29 regulates HIV Tat and morphine-mediated neuronal dysfunction. *Cell Death Dis*, *3*, e381.
- Huang, X., Yuan, T., Liang, M., Du, M., Xia, S., Dittmar, R., Wang, D., See, W., Costello, B. A., Quevedo, F., Tan, W., Nandy, D., Bevan, G. H., Longenbach, S., Sun, Z., Lu, Y., Wang, T., Thibodeau, S. N., Boardman, L., Kohli, M., & Wang, L. (2015). Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. *Eur Urol*, *67*, 33-41.
- Huang, X., Yuan, T., Tschannen, M., Sun, Z., Jacob, H., Du, M., Liang, M., Dittmar, R. L., Liu, Y., Liang, M., Kohli, M., Thibodeau, S. N., Boardman, L., & Wang, L. (2013). Characterization of human plasma-derived exosomal RNAs by deep sequencing. *BMC Genomics*, *14*, 319.

- Hurley, J. H., & Odorizzi, G. (2012). Get on the exosome bus with ALIX. *Nat Cell Biol*, *14*, 654-655.
- Iavello, A., Frech, V. S., Gai, C., Deregibus, M. C., Quesenberry, P. J., & Camussi, G. (2016). Role of Alix in miRNA packaging during extracellular vesicle biogenesis. *Int J Mol Med*, *37*, 958-966.
- Iraci, N., Leonardi, T., Gessler, F., Vega, B., & Pluchino, S. (2016). Focus on Extracellular Vesicles: Physiological Role and Signalling Properties of Extracellular Membrane Vesicles. *Int J Mol Sci*, *17*, 171.
- Izumi, H., Kosaka, N., Shimizu, T., Sekine, K., Ochiya, T., & Takase, M. (2012). Bovine milk contains microRNA and messenger RNA that are stable under degradative conditions. *J Dairy Sci*, *95*, 4831-4841.
- Janas, T., Janas, M. M., Sapon, K., & Janas, T. (2015). Mechanisms of RNA loading into exosomes. *FEBS Lett*, *589*, 1391-1398.
- Janas, T., Janas, T., & Yarus, M. (2006). Specific RNA binding to ordered phospholipid bilayers. *Nucleic Acids Res*, *34*, 2128-2136.
- Janas, T., Janas, T., & Yarus, M. (2012). Human tRNA(Sec) associates with HeLa membranes, cell lipid liposomes, and synthetic lipid bilayers. *RNA*, *18*, 2260-2268.
- Jansen, F., Yang, X., Proebsting, S., Hoelscher, M., Przybilla, D., Baumann, K., Schmitz, T., Dolf, A., Endl, E., Franklin, B. S., Sinning, J. M., Vasa-Nicotera, M., Nickenig, G., & Werner, N. (2014). MicroRNA expression in circulating microvesicles predicts cardiovascular events in patients with coronary artery disease. *J Am Heart Assoc*, *3*, e001249.
- Jaye, D. L., Bray, R. A., Gebel, H. M., Harris, W. A., & Waller, E. K. (2012). Translational applications of flow cytometry in clinical practice. *J Immunol*, *188*, 4715-4719.
- Jeppesen, D. K., Hvam, M. L., Primdahl-Bengtson, B., Boysen, A. T., Whitehead, B., Dyrskjot, L., Orntoft, T. F., Howard, K. A., & Ostenfeld, M. S. (2014). Comparative analysis of discrete exosome fractions obtained by differential centrifugation. *J Extracell Vesicles*, *3*, 25011.
- Ji, H., Chen, M., Greening, D. W., He, W., Rai, A., Zhang, W., & Simpson, R. J. (2014). Deep sequencing of RNA from three different extracellular vesicle (EV) subtypes released from the human LIM1863 colon cancer cell line uncovers distinct miRNA-enrichment signatures. *PLoS One*, *9*, e110314.
- Jia, S., Zocco, D., Samuels, M. L., Chou, M. F., Chammas, R., Skog, J., Zarovni, N., Momen-Heravi, F., & Kuo, W. P. (2014). Emerging technologies in extracellular vesicle-based molecular diagnostics. *Expert Rev Mol Diagn*, *14*, 307-321.
- Kahlert, C., Melo, S. A., Protopopov, A., Tang, J., Seth, S., Koch, M., Zhang, J., Weitz, J., Chin, L., Futreal, A., & Kalluri, R. (2014). Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. *J Biol Chem*, *289*, 3869-3875.
- Kalra, H., Adda, C. G., Liem, M., Ang, C. S., Mechler, A., Simpson, R. J., Hulett, M. D., & Mathivanan, S. (2013). Comparative proteomics evaluation of plasma exosome isolation techniques and assessment of the stability of exosomes in normal human blood plasma. *Proteomics*, *13*, 3354-3364.
- Kim, J., Lee, T., Kim, T. H., Lee, K. T., & Kim, H. (2012). An integrated approach of comparative genomics and heritability analysis of pig and human on obesity trait: evidence for candidate genes on human chromosome 2. *BMC Genomics*, *13*, 711.
- King, H. W., Michael, M. Z., & Gleadle, J. M. (2012). Hypoxic enhancement of exosome release by breast cancer cells. *BMC Cancer*, *12*, 421.
- Kogure, T., Lin, W. L., Yan, I. K., Braconi, C., & Patel, T. (2011). Intercellular nanovesicle-mediated microRNA transfer: a mechanism of environmental modulation of hepatocellular cancer cell growth. *Hepatology*, *54*, 1237-1248.
- Koltai, H., & Weingarten-Baror, C. (2008). Specificity of DNA microarray hybridization: characterization, effectors and approaches for data correction. *Nucleic Acids Res*, *36*, 2395-2405.

- Koppers-Lalic, D., Hackenberg, M., Bijnsdorp, I. V., van Eijndhoven, M. A., Sadek, P., Sie, D., Zini, N., Middeldorp, J. M., Ylstra, B., de Menezes, R. X., Wurdinger, T., Meijer, G. A., & Pegtel, D. M. (2014). Nontemplated nucleotide additions distinguish the small RNA composition in cells from exosomes. *Cell Rep*, *8*, 1649-1658.
- Kosaka, N., Iguchi, H., Hagiwara, K., Yoshioka, Y., Takeshita, F., & Ochiya, T. (2013). Neutral sphingomyelinase 2 (nSMase2)-dependent exosomal transfer of angiogenic microRNAs regulate cancer cell metastasis. *J Biol Chem*, *288*, 10849-10859.
- Kosaka, N., Iguchi, H., Yoshioka, Y., Takeshita, F., Matsuki, Y., & Ochiya, T. (2010). Secretory mechanisms and intercellular transfer of microRNAs in living cells. *J Biol Chem*, *285*, 17442-17452.
- Kosaka, N., Izumi, H., Sekine, K., & Ochiya, T. (2010). microRNA as a new immune-regulatory agent in breast milk. *Silence*, *1*, 7.
- Koshiol, J., Wang, E., Zhao, Y., Marincola, F., & Landi, M. T. (2010). Strengths and limitations of laboratory procedures for microRNA detection. *Cancer Epidemiol Biomarkers Prev*, *19*, 907-911.
- Kowal, J., Arras, G., Colombo, M., Jouve, M., Morath, J. P., Primdal-Bengtson, B., Dingli, F., Loew, D., Tkach, M., & Thery, C. (2016). Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. *Proc Natl Acad Sci U S A*, *113*, E968-977.
- Kucharzewska, P., Christianson, H. C., Welch, J. E., Svensson, K. J., Fredlund, E., Ringner, M., Morgelin, M., Bourseau-Guilmain, E., Bengzon, J., & Belting, M. (2013). Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. *Proc Natl Acad Sci U S A*, *110*, 7312-7317.
- Kulkarni, S., Kannan, M., & Atreya, C. D. (2010). Omic approaches to quality biomarkers for stored platelets: are we there yet? *Transfus Med Rev*, *24*, 211-217.
- Kwaan, H. C. (2010). Role of plasma proteins in whole blood viscosity: a brief clinical review. *Clin Hemorheol Microcirc*, *44*, 167-176.
- Lai, C. P., Kim, E. Y., Badr, C. E., Weissleder, R., Mempel, T. R., Tannous, B. A., & Breakefield, X. O. (2015). Visualization and tracking of tumour extracellular vesicle delivery and RNA translation using multiplexed reporters. *Nat Commun*, *6*, 7029.
- Lambertz, U., Oviedo Ovando, M. E., Vasconcelos, E. J., Unrau, P. J., Myler, P. J., & Reiner, N. E. (2015). Small RNAs derived from tRNAs and rRNAs are highly enriched in exosomes from both old and new world *Leishmania* providing evidence for conserved exosomal RNA Packaging. *BMC Genomics*, *16*, 151.
- Lamichhane, T. N., Leung, C. A., Douthett, L. Y., & Jay, S. M. (2017). Ethanol Induces Enhanced Vascularization Bioactivity of Endothelial Cell-Derived Extracellular Vesicles via Regulation of MicroRNAs and Long Non-Coding RNAs. *Sci Rep*, *7*, 13794.
- Lane, R. E., Korbie, D., Anderson, W., Vaidyanathan, R., & Trau, M. (2015). Analysis of exosome purification methods using a model liposome system and tunable-resistive pulse sensing. *Sci Rep*, *5*, 7639.
- Langer, K., Balthasar, S., Vogel, V., Dinauer, N., von Briesen, H., & Schubert, D. (2003). Optimization of the preparation process for human serum albumin (HSA) nanoparticles. *Int J Pharm*, *257*, 169-180.
- Lasda, E., & Parker, R. (2016). Circular RNAs Co-Precipitate with Extracellular Vesicles: A Possible Mechanism for circRNA Clearance. *PLoS One*, *11*, e0148407.
- Lasser, C., Alikhani, V. S., Ekstrom, K., Eldh, M., Paredes, P. T., Bossios, A., Sjostrand, M., Gabrielsson, S., Lotvall, J., & Valadi, H. (2011). Human saliva, plasma and breast milk exosomes contain RNA: uptake by macrophages. *J Transl Med*, *9*, 9.

- Lazaro-Ibanez, E., Sanz-Garcia, A., Visakorpi, T., Escobedo-Lucea, C., Siljander, P., Ayuso-Sacido, A., & Yliperttula, M. (2014). Different gDNA content in the subpopulations of prostate cancer extracellular vesicles: apoptotic bodies, microvesicles, and exosomes. *Prostate*, *74*, 1379-1390.
- Lee, J., McKinney, K. Q., Pavlopoulos, A. J., Niu, M., Kang, J. W., Oh, J. W., Kim, K. P., & Hwang, S. (2018). Altered Proteome of Extracellular Vesicles Derived from Bladder Cancer Patients Urine. *Mol Cells*.
- Lee, T. H., Chennakrishnaiah, S., Audemard, E., Montermini, L., Meehan, B., & Rak, J. (2014). Oncogenic ras-driven cancer cell vesiculation leads to emission of double-stranded DNA capable of interacting with target cells. *Biochem Biophys Res Commun*, *451*, 295-301.
- Lee, T. H., Chennakrishnaiah, S., Meehan, B., Montermini, L., Garnier, D., D'Asti, E., Hou, W., Magnus, N., Gayden, T., Jabado, N., Eppert, K., Majewska, L., & Rak, J. (2016). Barriers to horizontal cell transformation by extracellular vesicles containing oncogenic H-ras. *Oncotarget*, *7*, 51991-52002.
- Li, X., Blount, P. L., Vaughan, T. L., & Reid, B. J. (2011). Application of biomarkers in cancer risk management: evaluation from stochastic clonal evolutionary and dynamic system optimization points of view. *PLoS Comput Biol*, *7*, e1001087.
- Liga, A., Vliegthart, A. D., Oosthuyzen, W., Dear, J. W., & Kersaudy-Kerhoas, M. (2015). Exosome isolation: a microfluidic road-map. *Lab Chip*, *15*, 2388-2394.
- Lindberg, J., & Lundberg, J. (2010). The plasticity of the mammalian transcriptome. *Genomics*, *95*, 1-6.
- Liu, S., Sun, J., & Lan, Q. (2014). Glioblastoma microvesicles promote endothelial cell proliferation through Akt/beta-catenin pathway. *Int J Clin Exp Pathol*, *7*, 4857-4866.
- Lobb, R. J., Becker, M., Wen, S. W., Wong, C. S., Wiegmans, A. P., Leimgruber, A., & Moller, A. (2015). Optimized exosome isolation protocol for cell culture supernatant and human plasma. *J Extracell Vesicles*, *4*, 27031.
- Logozzi, M., De Milito, A., Lugini, L., Borghi, M., Calabro, L., Spada, M., Perdicchio, M., Marino, M. L., Federici, C., Iessi, E., Brambilla, D., Venturi, G., Lozupone, F., Santinami, M., Huber, V., Maio, M., Rivoltini, L., & Fais, S. (2009). High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. *PLoS One*, *4*, e5219.
- Longatti, A., Boyd, B., & Chisari, F. V. (2015). Virion-independent transfer of replication-competent hepatitis C virus RNA between permissive cells. *J Virol*, *89*, 2956-2961.
- Lotvall, J., Hill, A. F., Hochberg, F., Buzas, E. I., Di Vizio, D., Gardiner, C., Gho, Y. S., Kurochkin, I. V., Mathivanan, S., Quesenberry, P., Sahoo, S., Tahara, H., Wauben, M. H., Witwer, K. W., & Thery, C. (2014). Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. *J Extracell Vesicles*, *3*, 26913.
- Lunavat, T. R., Cheng, L., Kim, D. K., Bhadury, J., Jang, S. C., Lasser, C., Sharples, R. A., Lopez, M. D., Nilsson, J., Gho, Y. S., Hill, A. F., & Lotvall, J. (2015). Small RNA deep sequencing discriminates subsets of extracellular vesicles released by melanoma cells--Evidence of unique microRNA cargos. *RNA Biol*, *12*, 810-823.
- Ma, P., Pan, Y., Li, W., Sun, C., Liu, J., Xu, T., & Shu, Y. (2017). Extracellular vesicles-mediated noncoding RNAs transfer in cancer. *J Hematol Oncol*, *10*, 57.
- Maas, S. L., De Vrij, J., & Broekman, M. L. (2014). Quantification and size-profiling of extracellular vesicles using tunable resistive pulse sensing. *J Vis Exp*, e51623.
- Madhavan, B., Yue, S., Galli, U., Rana, S., Gross, W., Muller, M., Giese, N. A., Kalthoff, H., Becker, T., Buchler, M. W., & Zoller, M. (2015). Combined evaluation of a panel of protein and miRNA serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity. *Int J Cancer*, *136*, 2616-2627.

- Madison, M. N., Roller, R. J., & Okeoma, C. M. (2014). Human semen contains exosomes with potent anti-HIV-1 activity. *Retrovirology*, *11*, 102.
- Marcilla, A., Treliis, M., Cortes, A., Sotillo, J., Cantalapiedra, F., Minguez, M. T., Valero, M. L., Sanchez del Pino, M. M., Munoz-Antoli, C., Toledo, R., & Bernal, D. (2012). Extracellular vesicles from parasitic helminths contain specific excretory/secretory proteins and are internalized in intestinal host cells. *PLoS One*, *7*, e45974.
- Martinez-Lorenzo, M. J., Anel, A., Gamen, S., Monle n, I., Lasierra, P., Larrad, L., Pineiro, A., Alava, M. A., & Naval, J. (1999). Activated human T cells release bioactive Fas ligand and APO2 ligand in microvesicles. *J Immunol*, *163*, 1274-1281.
- Matsumoto, S., Sakata, Y., Suna, S., Nakatani, D., Usami, M., Hara, M., Kitamura, T., Hamasaki, T., Nanto, S., Kawahara, Y., & Komuro, I. (2013). Circulating p53-responsive microRNAs are predictive indicators of heart failure after acute myocardial infarction. *Circ Res*, *113*, 322-326.
- Matullo, G., Naccarati, A., & Pardini, B. (2015). microRNA expression profiling in bladder cancer: The challenge of Next Generation Sequencing in tissues and biofluids. *Int J Cancer*.
- McNamara, R. P., Costantini, L. M., Myers, T. A., Schouest, B., Maness, N. J., Griffith, J. D., Damania, B. A., MacLean, A. G., & Dittmer, D. P. (2018). Nef Secretion into Extracellular Vesicles or Exosomes Is Conserved across Human and Simian Immunodeficiency Viruses. *MBio*, *9*.
- Meckes, D. G., Jr., Gunawardena, H. P., Dekroon, R. M., Heaton, P. R., Edwards, R. H., Ozgur, S., Griffith, J. D., Damania, B., & Raab-Traub, N. (2013). Modulation of B-cell exosome proteins by gamma herpesvirus infection. *Proc Natl Acad Sci U S A*, *110*, E2925-2933.
- Meldrum, C., Doyle, M. A., & Tohill, R. W. (2011). Next-generation sequencing for cancer diagnostics: a practical perspective. *Clin Biochem Rev*, *32*, 177-195.
- Michael, A., Bajracharya, S. D., Yuen, P. S., Zhou, H., Star, R. A., Illei, G. G., & Alevizos, I. (2010). Exosomes from human saliva as a source of microRNA biomarkers. *Oral Dis*, *16*, 34-38.
- Millimaggi, D., Mari, M., D'Ascenzo, S., Carosa, E., Jannini, E. A., Zucker, S., Carta, G., Pavan, A., & Dolo, V. (2007). Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells. *Neoplasia*, *9*, 349-357.
- Moldovan, L., Batte, K. E., Trgovcich, J., Wisler, J., Marsh, C. B., & Piper, M. (2014). Methodological challenges in utilizing miRNAs as circulating biomarkers. *J Cell Mol Med*, *18*, 371-390.
- Momen-Heravi, F. (2017). Isolation of Extracellular Vesicles by Ultracentrifugation. *Methods Mol Biol*, *1660*, 25-32.
- Momen-Heravi, F., Bala, S., Bukong, T., & Szabo, G. (2014). Exosome-mediated delivery of functionally active miRNA-155 inhibitor to macrophages. *Nanomedicine*, *10*, 1517-1527.
- Momen-Heravi, F., Bala, S., Kodys, K., & Szabo, G. (2015). Exosomes derived from alcohol-treated hepatocytes horizontally transfer liver specific miRNA-122 and sensitize monocytes to LPS. *Sci Rep*, *5*, 9991.
- Momen-Heravi, F., Balaj, L., Alian, S., Mantel, P. Y., Halleck, A. E., Trachtenberg, A. J., Soria, C. E., Oquin, S., Bonebreak, C. M., Saracoglu, E., Skog, J., & Kuo, W. P. (2013). Current methods for the isolation of extracellular vesicles. *Biol Chem*, *394*, 1253-1262.
- Momen-Heravi, F., Balaj, L., Alian, S., Tigges, J., Toxavidis, V., Ericsson, M., Distel, R. J., Ivanov, A. R., Skog, J., & Kuo, W. P. (2012). Alternative methods for characterization of extracellular vesicles. *Front Physiol*, *3*, 354.
- Momen-Heravi, F., Balaj, L., Alian, S., Trachtenberg, A. J., Hochberg, F. H., Skog, J., & Kuo, W. P. (2012). Impact of biofluid viscosity on size and sedimentation efficiency of the isolated microvesicles. *Front Physiol*, *3*, 162.
- Momen-Heravi, F., Saha, B., Kodys, K., Catalano, D., Satishchandran, A., & Szabo, G. (2015). Increased number of circulating exosomes and their microRNA cargos are potential novel biomarkers in alcoholic hepatitis. *J Transl Med*, *13*, 261.

- Monleon, I., Martinez-Lorenzo, M. J., Monteagudo, L., Lasierra, P., Taules, M., Iturralde, M., Pineiro, A., Larrad, L., Alava, M. A., Naval, J., & Anel, A. (2001). Differential secretion of Fas ligand- or APO2 ligand/TNF-related apoptosis-inducing ligand-carrying microvesicles during activation-induced death of human T cells. *J Immunol*, *167*, 6736-6744.
- Moschos, S. A. (2012). Genomic biomarkers for patient selection and stratification: the cancer paradigm. *Bioanalysis*, *4*, 2499-2511.
- Moschos, S. A., Frick, M., Taylor, B., Turnpenny, P., Graves, H., Spink, K. G., Brady, K., Lamb, D., Collins, D., Rockel, T. D., Weber, M., Lazari, O., Perez-Tosar, L., Fancy, S. A., Laphorn, C., Green, M. X., Evans, S., Selby, M., Jones, G., Jones, L., Kearney, S., Mechiche, H., Gikunju, D., Subramanian, R., Uhlmann, E., Jurk, M., Vollmer, J., Ciaramella, G., & Yeadon, M. (2011). Uptake, efficacy, and systemic distribution of naked, inhaled short interfering RNA (siRNA) and locked nucleic acid (LNA) antisense. *Mol Ther*, *19*, 2163-2168.
- Nakai, W., Yoshida, T., Diez, D., Miyatake, Y., Nishibu, T., Imawaka, N., Naruse, K., Sadamura, Y., & Hanayama, R. (2016). A novel affinity-based method for the isolation of highly purified extracellular vesicles. *Sci Rep*, *6*, 33935.
- Nawaz, M., Camussi, G., Valadi, H., Nazarenko, I., Ekstrom, K., Wang, X., Principe, S., Shah, N., Ashraf, N. M., Fatima, F., Neder, L., & Kislinger, T. (2014). The emerging role of extracellular vesicles as biomarkers for urogenital cancers. *Nat Rev Urol*, *11*, 688-701.
- Nolte-'t Hoen, E. N., Buermans, H. P., Waasdorp, M., Stoorvogel, W., Wauben, M. H., & 't Hoen, P. A. (2012). Deep sequencing of RNA from immune cell-derived vesicles uncovers the selective incorporation of small non-coding RNA biotypes with potential regulatory functions. *Nucleic Acids Res*, *40*, 9272-9285.
- Nordin, J. Z., Lee, Y., Vader, P., Mager, I., Johansson, H. J., Heusermann, W., Wiklander, O. P., Hallbrink, M., Seow, Y., Bultema, J. J., Gilthorpe, J., Davies, T., Fairchild, P. J., Gabrielsson, S., Meisner-Kober, N. C., Lehtio, J., Smith, C. I., Wood, M. J., & El Andaloussi, S. (2015). Ultrafiltration with size-exclusion liquid chromatography for high yield isolation of extracellular vesicles preserving intact biophysical and functional properties. *Nanomedicine*, *11*, 879-883.
- O'Connell, R. M., Rao, D. S., Chaudhuri, A. A., & Baltimore, D. (2010). Physiological and pathological roles for microRNAs in the immune system. *Nat Rev Immunol*, *10*, 111-122.
- Odoux, C., Fohrer, H., Hoppo, T., Guzik, L., Stolz, D. B., Lewis, D. W., Gollin, S. M., Gamblin, T. C., Geller, D. A., & Lagasse, E. (2008). A stochastic model for cancer stem cell origin in metastatic colon cancer. *Cancer Res*, *68*, 6932-6941.
- Ogata-Kawata, H., Izumiya, M., Kurioka, D., Honma, Y., Yamada, Y., Furuta, K., Gunji, T., Ohta, H., Okamoto, H., Sonoda, H., Watanabe, M., Nakagama, H., Yokota, J., Kohno, T., & Tsuchiya, N. (2014). Circulating exosomal microRNAs as biomarkers of colon cancer. *PLoS One*, *9*, e92921.
- Okazaki, Y., Furuno, M., Kasukawa, T., Adachi, J., Bono, H., Kondo, S., Nikaido, I., Osato, N., Saito, R., Suzuki, H., Yamanaka, I., Kiyosawa, H., Yagi, K., Tomaru, Y., Hasegawa, Y., Nogami, A., Schonbach, C., Gojobori, T., Baldarelli, R., Hill, D. P., Bult, C., Hume, D. A., Quackenbush, J., Schriml, L. M., Kanapin, A., Matsuda, H., Batalov, S., Beisel, K. W., Blake, J. A., Bradt, D., Brusic, V., Chothia, C., Corbani, L. E., Cousins, S., Dalla, E., Dragani, T. A., Fletcher, C. F., Forrest, A., Frazer, K. S., Gaasterland, T., Gariboldi, M., Gissi, C., Godzik, A., Gough, J., Grimmond, S., Gustincich, S., Hirokawa, N., Jackson, I. J., Jarvis, E. D., Kanai, A., Kawaji, H., Kawasawa, Y., Kedzierski, R. M., King, B. L., Konagaya, A., Kurochkin, I. V., Lee, Y., Lenhard, B., Lyons, P. A., Maglott, D. R., Maltais, L., Marchionni, L., McKenzie, L., Miki, H., Nagashima, T., Numata, K., Okido, T., Pavan, W. J., Perte, G., Pesole, G., Petrovsky, N., Pillai, R., Pontius, J. U., Qi, D., Ramachandran, S., Ravasi, T., Reed, J. C., Reed, D. J., Reid, J., Ring, B. Z., Ringwald, M., Sandelin, A., Schneider, C., Semple, C. A., Setou, M., Shimada, K., Sultana, R., Takenaka, Y., Taylor, M. S., Teasdale, R. D., Tomita, M., Verardo, R., Wagner, L., Wahlestedt, C., Wang, Y., Watanabe, Y.,

- Wells, C., Wilming, L. G., Wynshaw-Boris, A., Yanagisawa, M., Yang, I., Yang, L., Yuan, Z., Zavolan, M., Zhu, Y., Zimmer, A., Carninci, P., Hayatsu, N., Hirozane-Kishikawa, T., Konno, H., Nakamura, M., Sakazume, N., Sato, K., Shiraki, T., Waki, K., Kawai, J., Aizawa, K., Arakawa, T., Fukuda, S., Hara, A., Hashizume, W., Imotani, K., Ishii, Y., Itoh, M., Kagawa, I., Miyazaki, A., Sakai, K., Sasaki, D., Shibata, K., Shinagawa, A., Yasunishi, A., Yoshino, M., Waterston, R., Lander, E. S., Rogers, J., Birney, E., Hayashizaki, Y., Consortium, F., I, R. G. E. R. G. P., & Team, I. I. (2002). Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. *Nature*, *420*, 563-573.
- Pang, J. M., Gorringer, K. L., Wong, S. Q., Dobrovic, A., Campbell, I. G., & Fox, S. B. (2015). Appraisal of the technologies and review of the genomic landscape of ductal carcinoma in situ of the breast. *Breast Cancer Res*, *17*, 80.
- Pegtel, D. M., Cosmopoulos, K., Thorley-Lawson, D. A., van Eijndhoven, M. A., Hopmans, E. S., Lindenberg, J. L., de Gruijl, T. D., Wurdinger, T., & Middeldorp, J. M. (2010). Functional delivery of viral miRNAs via exosomes. *Proc Natl Acad Sci U S A*, *107*, 6328-6333.
- Peinado, H., Aleckovic, M., Lavotshkin, S., Matei, I., Costa-Silva, B., Moreno-Bueno, G., Hergueta-Redondo, M., Williams, C., Garcia-Santos, G., Ghajar, C., Nitadori-Hoshino, A., Hoffman, C., Badal, K., Garcia, B. A., Callahan, M. K., Yuan, J., Martins, V. R., Skog, J., Kaplan, R. N., Brady, M. S., Wolchok, J. D., Chapman, P. B., Kang, Y., Bromberg, J., & Lyden, D. (2012). Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. *Nat Med*, *18*, 883-891.
- Pepys, M. B., & Hirschfield, G. M. (2003). C-reactive protein: a critical update. *J Clin Invest*, *111*, 1805-1812.
- Properzi, F., Logozzi, M., & Fais, S. (2013). Exosomes: the future of biomarkers in medicine. *Biomark Med*, *7*, 769-778.
- Qian, X., Ba, Y., Zhuang, Q., & Zhong, G. (2014). RNA-Seq technology and its application in fish transcriptomics. *OMICS*, *18*, 98-110.
- Raj, D. A., Fiume, I., Capasso, G., & Pocsfalvi, G. (2012). A multiplex quantitative proteomics strategy for protein biomarker studies in urinary exosomes. *Kidney Int*, *81*, 1263-1272.
- RamachandraRao, S. P., Matthias, M. A., Kokoy-Mondragon, C., Aghania, E., Park, C., Kong, C., Ishaya, M., Madrigal, A., Horng, J., Khoshaba, R., Bounkhoun, A., Basilico, F., De Palma, A., Agresta, A. M., Awdishu, L., Naviaux, R. K., Vinetz, J. M., & Mauri, P. (2015). Proteomic analysis of urine exosomes reveals renal tubule response to leptospiral colonization in experimentally infected rats. *PLoS Negl Trop Dis*, *9*, e0003640.
- Rana, S., Malinowska, K., & Zoller, M. (2013). Exosomal tumor microRNA modulates premetastatic organ cells. *Neoplasia*, *15*, 281-295.
- Raposo, G., & Stoorvogel, W. (2013). Extracellular vesicles: exosomes, microvesicles, and friends. *J Cell Biol*, *200*, 373-383.
- Rekker, K., Saare, M., Roost, A. M., Kubo, A. L., Zarovni, N., Chiesi, A., Salumets, A., & Peters, M. (2014). Comparison of serum exosome isolation methods for microRNA profiling. *Clin Biochem*, *47*, 135-138.
- Saa, P., Yakovleva, O., de Castro, J., Vasilyeva, I., De Paoli, S. H., Simak, J., & Cervenakova, L. (2014). First demonstration of transmissible spongiform encephalopathy-associated prion protein (PrP^{TSE}) in extracellular vesicles from plasma of mice infected with mouse-adapted variant Creutzfeldt-Jakob disease by in vitro amplification. *J Biol Chem*, *289*, 29247-29260.
- Saha, B., Momen-Heravi, F., Furi, I., Kodys, K., Catalano, D., Gangopadhyay, A., Haraszti, R., Satishchandran, A., Iracheta-Vellve, A., Adejumo, A., Shaffer, S. A., & Szabo, G. (2017). Extracellular vesicles from mice with alcoholic liver disease carry a distinct protein cargo and induce macrophage activation via Hsp90. *Hepatology*.

- Saha, B., Momen-Heravi, F., Kodys, K., & Szabo, G. (2015). MicroRNA Cargo of Extracellular Vesicles from Alcohol-Exposed Monocytes Signals Naive Monocytes to Differentiate into M2 Macrophages. *J Biol Chem*.
- Saha, B., Momen-Heravi, F., Kodys, K., & Szabo, G. (2016). MicroRNA Cargo of Extracellular Vesicles from Alcohol-exposed Monocytes Signals Naive Monocytes to Differentiate into M2 Macrophages. *J Biol Chem*, *291*, 149-159.
- Salter, S. J., Cox, M. J., Turek, E. M., Calus, S. T., Cookson, W. O., Moffatt, M. F., Turner, P., Parkhill, J., Loman, N. J., & Walker, A. W. (2014). Reagent and laboratory contamination can critically impact sequence-based microbiome analyses. *BMC Biol*, *12*, 87.
- San Lucas, F. A., Allenson, K., Bernard, V., Castillo, J., Kim, D., Ellis, K., Ehli, E. A., Davies, G. E., Petersen, J. L., Li, D., Wolff, R., Katz, M., Varadhachary, G., Wistuba, I., Maitra, A., & Alvarez, H. (2015). Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes. *Ann Oncol*.
- Sansone, P., Savini, C., Kurelac, I., Chang, Q., Amato, L. B., Strillacci, A., Stepanova, A., Iommarini, L., Mastroleo, C., Daly, L., Galkin, A., Thakur, B. K., Soplop, N., Uryu, K., Hoshino, A., Norton, L., Bonafe, M., Cricca, M., Gasparre, G., Lyden, D., & Bromberg, J. (2017). Packaging and transfer of mitochondrial DNA via exosomes regulate escape from dormancy in hormonal therapy-resistant breast cancer. *Proc Natl Acad Sci U S A*, *114*, E9066-E9075.
- Santangelo, L., Giurato, G., Cicchini, C., Montaldo, C., Mancone, C., Tarallo, R., Battistelli, C., Alonzi, T., Weisz, A., & Tripodi, M. (2016). The RNA-Binding Protein SYNCRIP Is a Component of the Hepatocyte Exosomal Machinery Controlling MicroRNA Sorting. *Cell Rep*, *17*, 799-808.
- Saunderson, S. C., Schuberth, P. C., Dunn, A. C., Miller, L., Hock, B. D., MacKay, P. A., Koch, N., Jack, R. W., & McLellan, A. D. (2008). Induction of exosome release in primary B cells stimulated via CD40 and the IL-4 receptor. *J Immunol*, *180*, 8146-8152.
- Schillaci, O., Fontana, S., Monteleone, F., Taverna, S., Di Bella, M. A., Di Vizio, D., & Alessandro, R. (2017). Exosomes from metastatic cancer cells transfer amoeboid phenotype to non-metastatic cells and increase endothelial permeability: their emerging role in tumor heterogeneity. *Sci Rep*, *7*, 4711.
- Schmieder, R., & Edwards, R. (2011). Fast identification and removal of sequence contamination from genomic and metagenomic datasets. *PLoS One*, *6*, e17288.
- Selmaj, I., Cichalewska, M., Namiecinska, M., Galazka, G., Horzelski, W., Selmaj, K. W., & Mycko, M. P. (2017). Global exosome transcriptome profiling reveals biomarkers for multiple sclerosis. *Ann Neurol*, *81*, 703-717.
- Shen, Y. J., Le Bert, N., Chitre, A. A., Koo, C. X., Nga, X. H., Ho, S. S., Khatoo, M., Tan, N. Y., Ishii, K. J., & Gasser, S. (2015). Genome-derived cytosolic DNA mediates type I interferon-dependent rejection of B cell lymphoma cells. *Cell Rep*, *11*, 460-473.
- Shurtleff, M. J., Temoche-Diaz, M. M., Karfilis, K. V., Ri, S., & Schekman, R. (2016). Y-box protein 1 is required to sort microRNAs into exosomes in cells and in a cell-free reaction. *Elife*, *5*.
- Shurtleff, M. J., Yao, J., Qin, Y., Nottingham, R. M., Temoche-Diaz, M. M., Schekman, R., & Lambowitz, A. M. (2017). Broad role for YBX1 in defining the small noncoding RNA composition of exosomes. *Proc Natl Acad Sci U S A*, *114*, E8987-E8995.
- Sikkema-Raddatz, B., Johansson, L. F., de Boer, E. N., Almomani, R., Boven, L. G., van den Berg, M. P., van Spaendonck-Zwarts, K. Y., van Tintelen, J. P., Sijmons, R. H., Jongbloed, J. D., & Sinke, R. J. (2013). Targeted next-generation sequencing can replace Sanger sequencing in clinical diagnostics. *Hum Mutat*, *34*, 1035-1042.
- Silva, J., Garcia, V., Zaballos, A., Provencio, M., Lombardia, L., Almonacid, L., Garcia, J. M., Dominguez, G., Pena, C., Diaz, R., Herrera, M., Varela, A., & Bonilla, F. (2011). Vesicle-related microRNAs in

- plasma of nonsmall cell lung cancer patients and correlation with survival. *Eur Respir J*, *37*, 617-623.
- Sivadasan, P., Gupta, M. K., Sathe, G. J., Balakrishnan, L., Palit, P., Gowda, H., Suresh, A., Kuriakose, M. A., & Sirdeshmukh, R. (2015). Human salivary proteome - a resource of potential biomarkers for oral cancer. *J Proteomics*, *127*, 89-95.
- Skog, J., Wurdinger, T., van Rijn, S., Meijer, D. H., Gainche, L., Sena-Estevés, M., Curry, W. T., Jr., Carter, B. S., Krichevsky, A. M., & Breakefield, X. O. (2008). Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. *Nat Cell Biol*, *10*, 1470-1476.
- Sohn, W., Kim, J., Kang, S. H., Yang, S. R., Cho, J. Y., Cho, H. C., Shim, S. G., & Paik, Y. H. (2015). Serum exosomal microRNAs as novel biomarkers for hepatocellular carcinoma. *Exp Mol Med*, *47*, e184.
- Sole, C., Cortes-Hernandez, J., Felip, M. L., Vidal, M., & Ordi-Ros, J. (2015). miR-29c in urinary exosomes as predictor of early renal fibrosis in lupus nephritis. *Nephrol Dial Transplant*, *30*, 1488-1496.
- Sorefan, K., Pais, H., Hall, A. E., Kozomara, A., Griffiths-Jones, S., Moulton, V., & Dalmy, T. (2012). Reducing ligation bias of small RNAs in libraries for next generation sequencing. *Silence*, *3*, 4.
- Squadrito, M. L., Baer, C., Burdet, F., Maderna, C., Gilfillan, G. D., Lyle, R., Ibberson, M., & De Palma, M. (2014). Endogenous RNAs modulate microRNA sorting to exosomes and transfer to acceptor cells. *Cell Rep*, *8*, 1432-1446.
- Stuopelyte, K., Daniunaite, K., Bakavicius, A., Lazutka, J. R., Jankevicius, F., & Jarmalaite, S. (2016). The utility of urine-circulating miRNAs for detection of prostate cancer. *Br J Cancer*, *115*, 707-715.
- Sun, J., Aswath, K., Schroeder, S. G., Lippolis, J. D., Reinhardt, T. A., & Sonstegard, T. S. (2015). MicroRNA expression profiles of bovine milk exosomes in response to *Staphylococcus aureus* infection. *BMC Genomics*, *16*, 806.
- Szabo, G., & Momen-Heravi, F. (2017). Extracellular vesicles in liver disease and potential as biomarkers and therapeutic targets. *Nat Rev Gastroenterol Hepatol*, *14*, 455-466.
- Tabor, H. K., Risch, N. J., & Myers, R. M. (2002). Candidate-gene approaches for studying complex genetic traits: practical considerations. *Nat Rev Genet*, *3*, 391-397.
- Takahashi, A., Okada, R., Nagao, K., Kawamata, Y., Hanyu, A., Yoshimoto, S., Takasugi, M., Watanabe, S., Kanemaki, M. T., Obuse, C., & Hara, E. (2017). Exosomes maintain cellular homeostasis by excreting harmful DNA from cells. *Nat Commun*, *8*, 15287.
- Tan, K. H., Tan, S. S., Ng, M. J., Tey, W. S., Sim, W. K., Allen, J. C., & Lim, S. K. (2017). Extracellular vesicles yield predictive pre-eclampsia biomarkers. *J Extracell Vesicles*, *6*, 1408390.
- Tanaka, Y., Kamohara, H., Kinoshita, K., Kurashige, J., Ishimoto, T., Iwatsuki, M., Watanabe, M., & Baba, H. (2013). Clinical impact of serum exosomal microRNA-21 as a clinical biomarker in human esophageal squamous cell carcinoma. *Cancer*, *119*, 1159-1167.
- Tassew, N. G., Charish, J., Shabanzadeh, A. P., Luga, V., Harada, H., Farhani, N., D'Onofrio, P., Choi, B., Ellabban, A., Nickerson, P. E. B., Wallace, V. A., Koeberle, P. D., Wrana, J. L., & Monnier, P. P. (2017). Exosomes Mediate Mobilization of Autocrine Wnt10b to Promote Axonal Regeneration in the Injured CNS. *Cell Rep*, *20*, 99-111.
- Tauro, B. J., Greening, D. W., Mathias, R. A., Mathivanan, S., Ji, H., & Simpson, R. J. (2013). Two distinct populations of exosomes are released from LIM1863 colon carcinoma cell-derived organoids. *Mol Cell Proteomics*, *12*, 587-598.
- Taylor, D. D., & Gercel-Taylor, C. (2008). MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. *Gynecol Oncol*, *110*, 13-21.
- Teng, Y., Ren, Y., Hu, X., Mu, J., Samykutty, A., Zhuang, X., Deng, Z., Kumar, A., Zhang, L., Merchant, M. L., Yan, J., Miller, D. M., & Zhang, H. G. (2017). MVP-mediated exosomal sorting of miR-193a promotes colon cancer progression. *Nat Commun*, *8*, 14448.

- Thakur, B. K., Zhang, H., Becker, A., Matei, I., Huang, Y., Costa-Silva, B., Zheng, Y., Hoshino, A., Brazier, H., Xiang, J., Williams, C., Rodriguez-Barrueco, R., Silva, J. M., Zhang, W., Hearn, S., Elemento, O., Paknejad, N., Manova-Todorova, K., Welte, K., Bromberg, J., Peinado, H., & Lyden, D. (2014). Double-stranded DNA in exosomes: a novel biomarker in cancer detection. *Cell Res*, *24*, 766-769.
- Thery, C., Amigorena, S., Raposo, G., & Clayton, A. (2006). Isolation and characterization of exosomes from cell culture supernatants and biological fluids. *Curr Protoc Cell Biol, Chapter 3*, Unit 3 22.
- Thery, C., Ostrowski, M., & Segura, E. (2009). Membrane vesicles as conveyors of immune responses. *Nat Rev Immunol*, *9*, 581-593.
- Thomas, S. N., Liao, Z., Clark, D., Chen, Y., Samadani, R., Mao, L., Ann, D. K., Baulch, J. E., Shapiro, P., & Yang, A. J. (2013). Exosomal Proteome Profiling: A Potential Multi-Marker Cellular Phenotyping Tool to Characterize Hypoxia-Induced Radiation Resistance in Breast Cancer. *Proteomes*, *1*, 87-108.
- Tiberio, P., Callari, M., Angeloni, V., Daidone, M. G., & Appierto, V. (2015). Challenges in using circulating miRNAs as cancer biomarkers. *Biomed Res Int*, *2015*, 731479.
- Tkach, M., Kowal, J., Zucchetti, A. E., Enserink, L., Jouve, M., Lankar, D., Saitakis, M., Martin-Jaular, L., & Thery, C. (2017). Qualitative differences in T-cell activation by dendritic cell-derived extracellular vesicle subtypes. *EMBO J*, *36*, 3012-3028.
- Tringe, S. G., & Rubin, E. M. (2005). Metagenomics: DNA sequencing of environmental samples. *Nat Rev Genet*, *6*, 805-814.
- Turchinovich, A., Weiz, L., Langheinz, A., & Burwinkel, B. (2011). Characterization of extracellular circulating microRNA. *Nucleic Acids Res*, *39*, 7223-7233.
- Valadi, H., Ekstrom, K., Bossios, A., Sjostrand, M., Lee, J. J., & Lotvall, J. O. (2007). Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat Cell Biol*, *9*, 654-659.
- Valencia, K., Luis-Ravelo, D., Bovy, N., Anton, I., Martinez-Canarias, S., Zanduetta, C., Ormazabal, C., Struman, I., Tabruyn, S., Rebmann, V., De Las Rivas, J., Gुरुceaga, E., Bandres, E., & Lecanda, F. (2014). miRNA cargo within exosome-like vesicle transfer influences metastatic bone colonization. *Mol Oncol*, *8*, 689-703.
- van der Pol, E., Boing, A. N., Harrison, P., Sturk, A., & Nieuwland, R. (2012). Classification, functions, and clinical relevance of extracellular vesicles. *Pharmacol Rev*, *64*, 676-705.
- van der Pol, E., Hoekstra, A. G., Sturk, A., Otto, C., van Leeuwen, T. G., & Nieuwland, R. (2010). Optical and non-optical methods for detection and characterization of microparticles and exosomes. *J Thromb Haemost*, *8*, 2596-2607.
- Van Deun, J., Mestdagh, P., Sormunen, R., Cocquyt, V., Vermaelen, K., Vandesompele, J., Bracke, M., De Wever, O., & Hendrix, A. (2014). The impact of disparate isolation methods for extracellular vesicles on downstream RNA profiling. *J Extracell Vesicles*, *3*.
- Verma, M., Lam, T. K., Hebert, E., & Divi, R. L. (2015). Extracellular vesicles: potential applications in cancer diagnosis, prognosis, and epidemiology. *BMC Clin Pathol*, *15*, 6.
- Villarroya-Beltri, C., Gutierrez-Vazquez, C., Sanchez-Cabo, F., Perez-Hernandez, D., Vazquez, J., Martin-Cofreces, N., Martinez-Herrera, D. J., Pascual-Montano, A., Mittelbrunn, M., & Sanchez-Madrid, F. (2013). Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs. *Nat Commun*, *4*, 2980.
- Vojtech, L., Woo, S., Hughes, S., Levy, C., Ballweber, L., Sauteraud, R. P., Strobl, J., Westerberg, K., Gottardo, R., Tewari, M., & Hladik, F. (2014). Exosomes in human semen carry a distinctive repertoire of small non-coding RNAs with potential regulatory functions. *Nucleic Acids Res*, *42*, 7290-7304.
- Wang, H., Hou, L., Li, A., Duan, Y., Gao, H., & Song, X. (2014). Expression of serum exosomal microRNA-21 in human hepatocellular carcinoma. *Biomed Res Int*, *2014*, 864894.

- Wang, H., Nettleton, D., & Ying, K. (2014). Copy number variation detection using next generation sequencing read counts. *BMC Bioinformatics*, *15*, 109.
- Wang, Z., Gerstein, M., & Snyder, M. (2009). RNA-Seq: a revolutionary tool for transcriptomics. *Nat Rev Genet*, *10*, 57-63.
- Wang, Z., Wu, H. J., Fine, D., Schmulen, J., Hu, Y., Godin, B., Zhang, J. X., & Liu, X. (2013). Ciliated micropillars for the microfluidic-based isolation of nanoscale lipid vesicles. *Lab Chip*, *13*, 2879-2882.
- Webber, J., Stone, T. C., Katilius, E., Smith, B. C., Gordon, B., Mason, M. D., Tabi, Z., Brewis, I. A., & Clayton, A. (2014). Proteomics analysis of cancer exosomes using a novel modified aptamer-based array (SOMAscan) platform. *Mol Cell Proteomics*, *13*, 1050-1064.
- Wiley, R. D., & Gummuluru, S. (2006). Immature dendritic cell-derived exosomes can mediate HIV-1 trans infection. *Proc Natl Acad Sci U S A*, *103*, 738-743.
- Willis, J. C., & Lord, G. M. (2015). Immune biomarkers: the promises and pitfalls of personalized medicine. *Nat Rev Immunol*, *15*, 323-329.
- Witwer, K. W. (2015). Circulating microRNA biomarker studies: pitfalls and potential solutions. *Clin Chem*, *61*, 56-63.
- Witwer, K. W., Buzas, E. I., Bemis, L. T., Bora, A., Lasser, C., Lotvall, J., Nolte-'t Hoen, E. N., Piper, M. G., Sivaraman, S., Skog, J., Thery, C., Wauben, M. H., & Hochberg, F. (2013). Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. *J Extracell Vesicles*, *2*.
- Wu, M., Ouyang, Y., Wang, Z., Zhang, R., Huang, P. H., Chen, C., Li, H., Li, P., Quinn, D., Dao, M., Suresh, S., Sadovsky, Y., & Huang, T. J. (2017). Isolation of exosomes from whole blood by integrating acoustics and microfluidics. *Proc Natl Acad Sci U S A*, *114*, 10584-10589.
- Xiang, X., Poliakov, A., Liu, C., Liu, Y., Deng, Z. B., Wang, J., Cheng, Z., Shah, S. V., Wang, G. J., Zhang, L., Grizzle, W. E., Mobley, J., & Zhang, H. G. (2009). Induction of myeloid-derived suppressor cells by tumor exosomes. *Int J Cancer*, *124*, 2621-2633.
- Xu, B., Zhang, Y., Du, X. F., Li, J., Zi, H. X., Bu, J. W., Yan, Y., Han, H., & Du, J. L. (2017). Neurons secrete miR-132-containing exosomes to regulate brain vascular integrity. *Cell Res*, *27*, 882-897.
- Xu, F., Wang, W., Wang, P., Jun Li, M., Chung Sham, P., & Wang, J. (2012). A fast and accurate SNP detection algorithm for next-generation sequencing data. *Nat Commun*, *3*, 1258.
- Yaman Agaoglu, F., Kovancilar, M., Dizdar, Y., Darendeliler, E., Holdenrieder, S., Dalay, N., & Gezer, U. (2011). Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. *Tumour Biol*, *32*, 583-588.
- Yanez-Mo, M., Siljander, P. R., Andreu, Z., Zavec, A. B., Borrás, F. E., Buzas, E. I., Buzas, K., Casal, E., Cappello, F., Carvalho, J., Colas, E., Cordeiro-da Silva, A., Fais, S., Falcon-Perez, J. M., Ghobrial, I. M., Giesel, B., Gimona, M., Graner, M., Gursel, I., Gursel, M., Heegaard, N. H., Hendrix, A., Kierulf, P., Kokubun, K., Kosanovic, M., Kralj-Iglic, V., Kramer-Albers, E. M., Laitinen, S., Lasser, C., Lener, T., Ligeti, E., Line, A., Lipps, G., Llorente, A., Lotvall, J., Mancek-Keber, M., Marcilla, A., Mittelbrunn, M., Nazarenko, I., Nolte-'t Hoen, E. N., Nyman, T. A., O'Driscoll, L., Olivan, M., Oliveira, C., Pallinger, E., Del Portillo, H. A., Reventos, J., Rigau, M., Rohde, E., Sammar, M., Sanchez-Madrid, F., Santarem, N., Schallmoser, K., Ostenfeld, M. S., Stoorvogel, W., Stukelj, R., Van der Grein, S. G., Vasconcelos, M. H., Wauben, M. H., & De Wever, O. (2015). Biological properties of extracellular vesicles and their physiological functions. *J Extracell Vesicles*, *4*, 27066.
- Yang, V. K., Loughran, K. A., Meola, D. M., Juhr, C. M., Thane, K. E., Davis, A. M., & Hoffman, A. M. (2017). Circulating exosome microRNA associated with heart failure secondary to myxomatous mitral valve disease in a naturally occurring canine model. *J Extracell Vesicles*, *6*, 1350088.

- Yokoi, A., Yoshioka, Y., Yamamoto, Y., Ishikawa, M., Ikeda, S. I., Kato, T., Kiyono, T., Takeshita, F., Kajiyama, H., Kikkawa, F., & Ochiya, T. (2017). Malignant extracellular vesicles carrying MMP1 mRNA facilitate peritoneal dissemination in ovarian cancer. *Nat Commun*, *8*, 14470.
- Yuana, Y., Levels, J., Grootemaat, A., Sturk, A., & Nieuwland, R. (2014). Co-isolation of extracellular vesicles and high-density lipoproteins using density gradient ultracentrifugation. *J Extracell Vesicles*, *3*.
- Zappulli, V., Friis, K. P., Fitzpatrick, Z., Maguire, C. A., & Breakefield, X. O. (2016). Extracellular vesicles and intercellular communication within the nervous system. *J Clin Invest*, *126*, 1198-1207.
- Zhang, B., Wang, J., Wang, X., Zhu, J., Liu, Q., Shi, Z., Chambers, M. C., Zimmerman, L. J., Shaddox, K. F., Kim, S., Davies, S. R., Wang, S., Wang, P., Kinsinger, C. R., Rivers, R. C., Rodriguez, H., Townsend, R. R., Ellis, M. J., Carr, S. A., Tabb, D. L., Coffey, R. J., Slebos, R. J., Liebler, D. C., & Nci, C. (2014). Proteogenomic characterization of human colon and rectal cancer. *Nature*, *513*, 382-387.
- Zhang, X., Yuan, X., Shi, H., Wu, L., Qian, H., & Xu, W. (2015). Exosomes in cancer: small particle, big player. *J Hematol Oncol*, *8*, 83.
- Zhao, S., Fung-Leung, W. P., Bittner, A., Ngo, K., & Liu, X. (2014). Comparison of RNA-Seq and microarray in transcriptome profiling of activated T cells. *PLoS One*, *9*, e78644.
- Zheng, J., Hernandez, J. M., Doussot, A., Bojmar, L., Zambirinis, C. P., Costa-Silva, B., van Beek, E., Mark, M. T., Molina, H., Askan, G., Basturk, O., Gonen, M., Kingham, T. P., Allen, P. J., D'Angelica, M. I., DeMatteo, R. P., Lyden, D., & Jarnagin, W. R. (2018). Extracellular matrix proteins and carcinoembryonic antigen-related cell adhesion molecules characterize pancreatic duct fluid exosomes in patients with pancreatic cancer. *HPB (Oxford)*.
- Zhou, H., Yuen, P. S., Pisitkun, T., Gonzales, P. A., Yasuda, H., Dear, J. W., Gross, P., Knepper, M. A., & Star, R. A. (2006). Collection, storage, preservation, and normalization of human urinary exosomes for biomarker discovery. *Kidney Int*, *69*, 1471-1476.
- Zocco, D., Ferruzzi, P., Cappello, F., Kuo, W. P., & Fais, S. (2014). Extracellular vesicles as shuttles of tumor biomarkers and anti-tumor drugs. *Front Oncol*, *4*, 267.

EV classification based on mode of biogenesis

Exosomes	Microvesicles	Apoptotic bodies
<ul style="list-style-type: none">•Origin: budding of inter luminal multivesicular bodies of endosomal pathways•Size: 30-100 nm•Surface markers: Tetraspanins (CD61, CD81, CD82, CD9), ESCRT components, TSG101, Flotillin 1 and Flotillin 2, HSPs, ALIX, MFGE8	<ul style="list-style-type: none">•Origin: Outward budding of plasma membrane•Size: 50-1000 nm•Surface markers: AnnexinV, Integrins, CD40 ligand	<ul style="list-style-type: none">•Origin: Outward budding of plasma membrane in apoptotic cells•Size: 50-5000 nm•Surface Markers: AnnexinV, particularly enriched in phosphatidylserin

*ESCRT: Endosomal sorting complex required for transport complex, MFGE8: milk fat globule-EGF factor 8 protein, TSG101: tumor susceptibility gene 101, HSPs: heat shock proteins

Figure 1




Figure 2




Figure 3




Figure 4